View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 30, 2014	May 02, 2014
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Trading Symbol	LRCX
Entity Registrant Name	LAM RESEARCH CORP
Entity Central Index Key	0000707549
Current Fiscal Year End Date	--06-29
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		162,130,379

Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 30, 2014

Jun. 30, 2013

^[1]

ASSETS

Cash and cash equivalents

$ 1,292,301

$ 1,162,473

Short-term investments

1,462,171

1,334,745

Accounts receivable, less allowance for doubtful accounts of $5,377 as of March 30, 2014 and $5,448 as of June 30, 2013

818,390

602,624

Inventories

717,356

559,317

Prepaid expenses and other current assets

157,131

134,670

Total current assets

4,447,349

3,793,829

Property and equipment, net

552,591

603,910

Restricted cash and investments

143,914

166,536

Goodwill

1,457,320

1,452,196

Intangible assets, net

951,593

1,074,345

Other assets

154,600

159,499

Total assets

7,707,367

7,250,315

LIABILITIES AND STOCKHOLDERS' EQUITY

Trade accounts payable

252,517

200,254

Accrued expenses and other current liabilities

515,504

464,528

Deferred profit

257,283

225,038

Current portion of long-term debt, convertible notes, and capital leases

517,401

514,655

Total current liabilities

1,542,705

1,404,475

Long-term debt, convertible notes, and capital leases

810,688

789,256

Income taxes payable

251,080

246,479

Other long-term liabilities

111,346

134,313

Total liabilities

2,715,819

2,574,523

Commitments and contingencies

Senior convertible notes

184,256

186,920

Stockholders' equity:

Preferred stock, at par value of $0.001 per share; authorized - 5,000 shares; none outstanding

Common stock, at par value of $0.001 per share; authorized - 400,000 shares; issued and outstanding - 161,988 shares as of March 30, 2014 and 162,873 shares as of June 30, 2013

162

163

Additional paid-in capital

5,187,053

5,084,544

Treasury stock, at cost; 92,467 shares as of March 30, 2014 and 89,205 shares as of June 30, 2013

(3,724,434)

(3,539,830)

Accumulated other comprehensive loss

(27,071)

(28,693)

Retained earnings

3,371,582

2,972,688

Total stockholders' equity

4,807,292

4,488,872

Total liabilities and stockholders' equity

$ 7,707,367

$ 7,250,315

[1]	Derived from audited financial statements

Consolidated Balance Sheets (Parenthetical) - USD ($)
shares in Thousands, $ in Thousands

Mar. 30, 2014

Jun. 30, 2013

^[1]

Accounts receivable, allowance for doubtful accounts

$ 5,377

$ 5,448

Preferred stock, par value

$ 0.001

Preferred stock, shares authorized

5,000

Preferred stock, shares outstanding

Common stock, par value

$ 0.001

Common stock, shares authorized

400,000

Common stock, shares issued

161,988

162,873

Common stock, shares outstanding

161,988

162,873

Treasury stock, shares

92,467

89,205

[1]	Derived from audited financial statements

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Revenue	$ 1,227,392	$ 844,928	$ 3,358,512	$ 2,612,702
Cost of goods sold	696,594	505,096	1,908,067	1,623,570
Gross margin	530,798	339,832	1,450,445	989,132
Research and development	185,978	174,206	531,022	503,468
Selling, general and administrative	152,883	154,807	457,604	454,091
Total operating expenses	338,861	329,013	988,626	957,559
Operating income	191,937	10,819	461,819	31,573
Other expense, net	(9,855)	(15,834)	(27,954)	(39,162)
Income (loss) before income taxes	182,082	(5,015)	433,865	(7,589)
Income tax expense (benefit)	17,686	(24,011)	34,971	(35,761)
Net income	$ 164,396	$ 18,996	$ 398,894	$ 28,172
Net income per share:
Basic	$ 1.01	$ 0.12	$ 2.46	$ 0.16
Diluted	$ 0.96	$ 0.11	$ 2.33	$ 0.16
Number of shares used in per share calculations:
Basic	162,238	163,034	161,904	171,016
Diluted	171,636	168,504	171,051	174,306

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Net income	$ 164,396	$ 18,996	$ 398,894	$ 28,172
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(8,160)	(5,398)	1,680	(554)
Cash flow hedges:
Net unrealized gains (losses) during the period	(205)	8,400	8,632	10,028
Net gains reclassified into earnings	(3,248)	(5,389)	(10,066)	(3,100)
Net change	(3,453)	3,011	(1,434)	6,928
Available-for-sale investments:
Net unrealized gains (losses) during the period	(111)	67	962	(105)
Net losses (gains) reclassified into earnings	25	2,899	(120)	3,321
Net change	(86)	2,966	842	3,216
Defined benefit plan, net change in unrealized component	149	160	534	483
Net current-period other comprehensive income	(11,550)	739	1,622	10,073
Comprehensive income	$ 152,846	$ 19,735	$ 400,516	$ 38,245

Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands

9 Months Ended

Mar. 30, 2014

Mar. 31, 2013

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income

$ 398,894

$ 28,172

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

221,139

228,065

Deferred income taxes

11,641

(47,271)

Impairment of long-lived asset

11,632

Impairment of investments

3,711

Equity-based compensation expense

70,615

74,089

Amortization of convertible note discount

24,652

23,530

Other, net

4,428

31,915

Changes in operating assets and liabilities

(271,843)

202,734

Net cash provided by operating activities

471,158

544,945

CASH FLOWS FROM INVESTING ACTIVITIES:

Capital expenditures

(103,739)

(117,655)

Cash paid for business acquisition

(18,388)

(9,116)

Purchases of available-for-sale securities

(823,932)

(832,913)

Sales and maturities of available-for-sale securities

695,001

780,950

Repayments of notes receivable

10,000

Proceeds from sale of assets

21,635

660

Transfer of restricted cash and investments

28,722

147

Net cash used for investing activities

(190,701)

(177,927)

CASH FLOWS FROM FINANCING ACTIVITIES:

Principal payments on long-term debt and capital lease obligations

(919)

(1,536)

Excess tax benefit on equity-based compensation plans

(296)

(903)

Treasury stock purchases

(204,610)

(953,386)

Reissuances of treasury stock related to employee stock purchase plan

28,329

18,419

Proceeds from issuance of common stock

26,134

22,666

Net cash used for financing activities

(151,362)

(914,740)

Effect of exchange rate changes on cash

733

2,079

Net increase (decrease) in cash and cash equivalents

129,828

(545,643)

Cash and cash equivalents at beginning of period

1,162,473

^[1]

1,564,752

Cash and cash equivalents at end of period

$ 1,292,301

$ 1,019,109

[1]	Derived from audited financial statements

BASIS OF PRESENTATION

9 Months Ended

Mar. 30, 2014

BASIS OF PRESENTATION

NOTE 1 — BASIS OF PRESENTATION

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. The accompanying unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements of Lam Research Corporation (“Lam Research” or the “Company”) for the fiscal year ended June 30, 2013, which are included in the Annual Report on Form 10-K as of and for the year ended June 30, 2013 (the “2013 Form 10-K”). The Company’s Forms 10-K, Forms 10-Q and Forms 8-K are available online at the Securities and Exchange Commission website on the Internet. The address of that site is www.sec.gov . The Company also posts its Forms 10-K, Forms 10-Q and Forms 8-K on its corporate website at http://investor.lamresearch.com .

The consolidated financial statements include the accounts of Lam Research and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company’s reporting period is a 52/53-week fiscal year. The Company’s current fiscal year (the “2014 fiscal year”) will end June 29, 2014 and includes 52 weeks. The quarter ended March 30, 2014 (the “March 2014 quarter”) included 13 weeks. The quarter ended March 31, 2013 (the “March 2013 quarter”) included 14 weeks.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

RECENT ACCOUNTING PRONOUNCEMENTS

9 Months Ended

Mar. 30, 2014

RECENT ACCOUNTING PRONOUNCEMENTS

NOTE 2 — RECENT ACCOUNTING PRONOUNCEMENTS

In July 2013, the FASB released Accounting Standards Update 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” The new standard requires that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset for a net operating loss carryforward or other tax credit carryforward when settlement in this manner is available under the tax law. We are required to adopt this standard starting fiscal year 2015 and are currently in the process of determining the impact, if any, on our financial position.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6510796

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28359718&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6372559&loc=d3e725-108305

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 01
-Paragraph b
-Subparagraph 6
-Article 10

+ Details

EQUITY-BASED COMPENSATION PLANS

9 Months Ended

Mar. 30, 2014

EQUITY-BASED COMPENSATION PLANS

NOTE 3 — EQUITY-BASED COMPENSATION PLANS

The Company has stock plans that provide for grants of equity-based awards to eligible participants, including stock options and restricted stock units (“RSUs”), of Lam Research common stock (“Common Stock”). An option is a right to purchase Common Stock at a set price. An RSU award is an agreement to issue shares of Common Stock at the time of vesting. The Company’s options and RSU awards typically vest over a period of three years or less, although awards assumed in connection with the acquisition of Novellus Systems, Inc. (“Novellus”), have vesting terms up to four years. The Company also has an employee stock purchase plan that allows employees to purchase its Common Stock at a discount through payroll deductions.

The Company recognized the following equity-based compensation expense and related income tax benefit in the Condensed Consolidated Statements of Operations:


	Three Months Ended				Nine Months Ended
	March 30,		March 31,		March 30,		March 31,
	2014		2013		2014		2013
	(in millions)
Equity-based compensation expense	$	24.3	$	25.6	$	70.6	$	74.1
Income tax benefit related to equity-based compensation expense	$	4.1	$	4.3	$	11.7	$	13.3

The estimated fair value of the Company’s stock-based awards, less expected forfeitures, is amortized over the awards’ vesting term on a straight-line basis.

Stock Options and RSUs

The Lam Research Corporation 2007 Stock Incentive Plan and 2011 Stock Incentive Plan (collectively the “Stock Plans”) provide for the grant of non-qualified equity-based awards to eligible employees, consultants and advisors, and non-employee directors of the Company and its subsidiaries. As of March 30, 2014, there was a total of 6,395,328 shares reserved to cover options and RSUs issued and outstanding under the Plans. As of March 30, 2014, there were an additional 11,008,283 shares reserved and available for future equity-based awards under the Plans.

A summary of stock option activity under the Plans as of March 30, 2014 and changes during the nine months then ended is presented below:


Options	Shares (in thousands)			Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value as of March 30, 2014 (in thousands)
Outstanding at June 30, 2013		2,571		$	26.87		4.48
Granted		166		$	51.76
Exercised		(1,065	)	$	24.50
Forfeited or expired		(1	)	$	29.71

Outstanding at March 30, 2014		1,671		$	30.86		4.78	$	39,501

Exercisable at March 30, 2014		1,066		$	24.62		3.86	$	31,840

The fair value of the Company’s stock options was estimated using a Black-Scholes option valuation model. The total intrinsic value of options exercised during the three months ended March 30, 2014 and March 31, 2013 was $7.1 million and $8.0 million, respectively. The total intrinsic value of options exercised during the nine months ended March 30, 2014 and March 31, 2013 was $29.3 million and $12.7 million, respectively. As of March 30, 2014, there was $5.9 million of total unrecognized compensation cost related to unvested stock options granted and outstanding; that cost is expected to be recognized over a weighted-average remaining vesting period of 1.7 years.

A summary of the Company’s RSUs as of March 30, 2014 and changes during the nine months then ended is presented below:


	Shares			Average Grant-
Unvested Restricted Stock Units	(in thousands)			Date Fair Value
Unvested at June 30, 2013		4,842		$	39.32
Granted		1,376		$	49.47
Vested		(1,313	)	$	39.84
Forfeited		(181	)	$	39.48

Unvested at March 30, 2014		4,724		$	42.12

The fair value of the Company’s RSUs was calculated based upon the fair market value of Common Stock at the date of grant. As of March 30, 2014, there was $130.3 million of total unrecognized compensation expense related to unvested RSUs granted; that expense is expected to be recognized over a weighted-average remaining period of 1.9 years.

During the three months ended March 30, 2014, the Company issued restricted stock units with both a market condition and a service condition (market-based performance RSUs “market-based PRSUs”). Based upon the terms of such awards, the number of shares of Common Stock to be issued at vesting will range from 0% to 150% of the target amount, based on the total stockholder return (“TSR”) of Common Stock measured against the benchmark TSR of the Philadelphia Semiconductor Sector Index over a two and three year period, and continued employment. TSR is a measure of stock price appreciation in this performance period. As of March 30, 2014, 0.6 million market-based PRSUs were outstanding. These market-based performance restricted stock units generally vest two or three years from the grant date. Stock compensation expense for the market-based PRSUs was $1.2 million for the three and nine months ended March 30, 2014. No market-based PRSUs were awarded in earlier periods. The total unrecognized compensation expense and weighted-average remaining life for these awards is included in the above table.

ESPP

The 1999 Employee Stock Purchase Plan, as amended and restated (the “1999 ESPP”), allows employees to designate a portion of their base compensation to be withheld through payroll deductions and used to purchase Common Stock at a purchase price per share equal to the lower of 85% of the fair market value of Common Stock on the first or last day of the applicable purchase period. Each offering period generally lasts up to 12 months and includes up to three interim purchase dates. As of March 30, 2014, there was a total of 8,741,208 shares available for issuance under the 1999 ESPP.

Purchase rights under the 1999 ESPP were valued using the Black-Scholes option valuation model assuming no expected dividends and the following weighted-average assumptions for the three and nine months ended March 30, 2014:


	Three Months Ended			Nine Months Ended
	March 30,			March 30,
	2014			2014
Expected term (years)		0.51			0.68
Expected stock price volatility		28.89	%		30.24	%
Risk-free interest rate		0.09	%		0.07	%

As of March 30, 2014, there was $5.7 million of unrecognized compensation expense related to the 1999 ESPP, which is expected to be recognized over a remaining period of approximately 5 months.

FINANCIAL INSTRUMENTS

9 Months Ended

Mar. 30, 2014

FINANCIAL INSTRUMENTS

NOTE 4 — FINANCIAL INSTRUMENTS

The Company maintains an investment portfolio of various holdings, types, and maturities. The Company’s mutual funds, which are related to the Company’s obligations under the deferred compensation plan, are classified as trading securities. Investments classified as trading securities are recorded at fair value based upon quoted market prices. Differences between the cost and fair value of trading securities are recognized as other income (expense) in the Condensed Consolidated Statements of Operations. All of the Company’s other short-term investments are classified as available-for-sale and consequently are recorded in the Consolidated Balance Sheets at fair value with unrealized gains or losses reported as a separate component of accumulated other comprehensive income (loss), net of tax.

Fair Value

The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions that market participants would use when pricing the asset or liability.

A fair value hierarchy has been established that prioritizes the inputs to valuation techniques used to measure fair value. The level of an asset or liability in the hierarchy is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:

Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities with sufficient volume and frequency of transactions.

Level 2: Valuations based on observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or model-derived valuations techniques for which all significant inputs are observable in the market or can be corroborated by observable market data, for substantially the full term of the assets or liabilities.

Level 3: Valuations based on unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities and based on non-binding, broker-provided price quotes and may not have been corroborated by observable market data.

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis at March 30, 2014:


			Fair Value Measurement at March 30, 2014
			Quoted Prices in				Significant
			Active Markets for		Significant Other		Unobservable
			Identical Assets		Observable Inputs		Inputs
	Total		(Level 1)		(Level 2)		(Level 3)
	(In thousands)
Assets
Short-Term Investments
Money Market Funds	$	1,042,596	$	1,042,596	$	—	$	—
Municipal Notes and Bonds		248,949		—		248,949		—
US Treasury and Agencies		182,967		182,967		—		—
Government-Sponsored Enterprises		41,089		—		41,089		—
Foreign Government Bonds		34,988		—		34,988		—
Corporate Notes and Bonds		961,378		132,549		828,829		—
Mortgage Backed Securities - Residential		26,580		—		26,580		—
Mortgage Backed Securities - Commercial		104,857		—		104,857		—

Total Short-Term Investments	$	2,643,404	$	1,358,112	$	1,285,292	$	—
Mutual Funds		28,559		28,559		—		—
Derivative Assets		2,487		—		2,487		—

Total Assets	$	2,674,450	$	1,386,671	$	1,287,779	$	—

Liabilities
Derivative Liabilities	$	1,340	$	—	$	1,190	$	150

The amounts in the table above are reported in the Consolidated Balance Sheet as of March 30, 2014 as follows:


Reported Within:	Total		Level 1		Level 2		Level 3
	(In thousands)
Cash Equivalents	$	1,042,596	$	1,042,596	$	—	$	—
Short-Term Investments		1,462,171		176,879		1,285,292		—
Restricted Cash and Investments		138,637		138,637		—		—
Prepaid Expenses and Other Current Assets		2,487		—		2,487		—
Other Assets		28,559		28,559		—		—

Total Assets	$	2,674,450	$	1,386,671	$	1,287,779	$	—

Accrued Expenses and Other Current Liabilities	$	1,190	$	—	$	1,190	$	—
Other Non-current Liabilities		150		—		—		150

Total Liabilities	$	1,340	$	—	$	1,190	$	150

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis at June 30, 2013:


			Fair Value Measurement at June 30, 2013
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(In thousands)
Assets
Short-Term Investments
Money Market Funds	$	725,311	$	725,311	$	—	$	—
Municipal Notes and Bonds		268,746		—		268,746		—
US Treasury and Agencies		155,293		155,293		—		—
Government-Sponsored Enterprises		54,805		—		54,805		—
Foreign Government Bond		24,972		—		24,972		—
Corporate Notes and Bonds		860,492		164,885		695,607		—
Mortgage Backed Securities - Residential		27,365		—		27,365		—
Mortgage Backed Securities - Commercial		107,958		—		107,958		—

Total Short-Term Investments	$	2,224,942	$	1,045,489	$	1,179,453	$	—
Equities		7,096		7,096		—		—
Mutual Funds		18,216		18,216		—		—
Derivative Assets		4,929		—		4,929		—

Total Assets	$	2,255,183	$	1,070,801	$	1,184,382	$	—

Liabilities
Derivative Liabilities	$	1,815	$	—	$	1,620	$	195

The amounts in the table above are reported in the Consolidated Balance Sheet as of June 30, 2013 as follows:


Reported Within:	Total		Level 1		Level 2		Level 3
	(In thousands)
Cash Equivalents	$	725,311	$	725,311	$	—	$	—
Short-Term Investments		1,334,746		155,293		1,179,453		—
Restricted Cash and Investments		164,885		164,885		—		—
Prepaid Expenses and Other Current Assets		4,929		—		4,929		—
Other Assets		25,312		25,312		—		—

Total Assets	$	2,255,183	$	1,070,801	$	1,184,382	$	—

Accrued Expenses and Other Current Liabilities	$	1,620	$	—	$	1,620	$	—
Other Non-current Liabilities		195		—		—		195

Total Liabilities	$	1,815	$	—	$	1,620	$	195

The Company’s primary financial instruments include its cash, cash equivalents, short-term investments, restricted cash and investments, long-term investments, accounts receivable, accounts payable, long-term debt and capital leases, and foreign currency related derivatives. The estimated fair value of cash, accounts receivable and accounts payable approximates their carrying value due to the short period of time to their maturities. The estimated fair values of capital lease obligations approximate their carrying value as the substantial majority of these obligations have interest rates that adjust to market rates on a periodic basis. Refer to Note 13 for additional information regarding the fair value of the Company’s convertible notes.

Investments

The following tables summarize the Company’s investments:


	March 30, 2014									June 30, 2013
	Cost		Unrealized Gain		Unrealized (Loss)			Fair Value		Cost		Unrealized Gain		Unrealized Loss			Fair Value
	(In thousands)									(In thousands)
Cash	$	254,982	$	—	$	—		$	254,982	$	438,813	$	—	$	—		$	438,813
Fixed Income Money Market Funds		1,042,596		—		—			1,042,596		725,311		—		—			725,311
Municipal Notes and Bonds		248,050		927		(28	)		248,949		268,390		805		(449	)		268,746
US Treasury and Agencies		183,072		61		(166	)		182,967		155,648		18		(373	)		155,293
Government-Sponsored Enterprises		41,068		51		(30	)		41,089		54,835		65		(95	)		54,805
Foreign Government Bonds		34,979		95		(86	)		34,988		24,950		47		(25	)		24,972
Corporate Notes and Bonds		960,356		1,771		(749	)		961,378		861,109		1,328		(1,945	)		860,492
Mortgage Backed Securities - Residential		26,802		30		(252	)		26,580		27,618		29		(282	)		27,365
Mortgage Backed Securities - Commercial		105,264		141		(548	)		104,857		108,204		426		(672	)		107,958

Total Cash and Short -Term Investments	$	2,897,169	$	3,076	$	(1,859	)	$	2,898,386	$	2,664,878	$	2,718	$	(3,841	)	$	2,663,755

Publicly Traded Equity Security	$	—	$	—	$	—		$	—	$	5,610	$	1,486	$	—		$	7,096
Private Equity Security		—		—		—			—		5,000		—		—			5,000
Mutual Funds		25,656		2,903		—			28,559		16,611		1,619		(14	)		18,216

Total Financial Instruments	$	2,922,825	$	5,979	$	(1,859	)	$	2,926,945	$	2,692,099	$	5,823	$	(3,855	)	$	2,694,067

Reported Within
Cash and Cash Equivalents	$	1,292,301	$	—	$	—		$	1,292,301	$	1,162,473	$	—	$	—		$	1,162,473
Short-Term Investments		1,460,954		3,076		(1,859	)		1,462,171		1,335,868		2,718		(3,841	)		1,334,745
Restricted Cash and Investments		143,914		—		—			143,914		166,536		—		—			166,536
Other assets		25,656		2,903		—			28,559		27,222		3,105		(14	)		30,313

Total	$	2,922,825	$	5,979	$	(1,859	)	$	2,926,945	$	2,692,099	$	5,823	$	(3,855	)	$	2,694,067

The Company accounts for its investment portfolio at fair value. Realized gains (losses) for investment sales are specifically identified. Management assesses the fair value of investments in debt securities that are not actively traded through consideration of interest rates and their impact on the present value of the cash flows to be received from the investments. The Company also considers whether changes in the credit ratings of the issuer could impact the assessment of fair value. The Company did not recognize any losses on investments due to other-than-temporary impairments during the three and nine months ended March 30, 2014. The Company recognized a $3.7 million other-than-temporary impairment of a public equity investment during the three and nine months ended March 31, 2013. Additionally, gross realized gains and gross realized (losses) from sales of investments were approximately $0.4 million and $(0.7) million, respectively, in the three months ended March 30, 2014 and $0.2 million and $(0.4) million, respectively, in the three months ended March 31, 2013. Gross realized gains and gross realized (losses) from sales of investments were approximately $0.8 million and $(1.7) million, respectively, in the nine months ended March 30, 2014 and $1.4 million and $(1.1) million, respectively, in the nine months ended March 30, 2013.

The following is an analysis of the Company’s fixed income securities in unrealized loss positions:


	March 30, 2014
	Unrealized Losses					Unrealized Losses
	Less Than 12 Months					12 Months or Greater					Total
	Fair Value		Gross Unrealized Loss			Fair Value		Gross Unrealized Loss			Fair Value		Gross Unrealized Loss
	(In thousands)
Short-Term Investments
Municipal Notes and Bonds	$	17,114	$	(28	)	$	—	$	—		$	17,114	$	(28	)
US Treasury and Agencies		96,394		(166	)		—		—			96,394		(166	)
Government-Sponsored Enterprises		14,071		(30	)		—		—			14,071		(30	)
Foreign Government Bonds		18,487		(86	)		—		—			18,487		(86	)
Corporate Notes and Bonds		261,299		(729	)		6,465		(20	)		267,764		(749	)
Mortgage Backed Securities - Residential		20,974		(243	)		127		(9	)		21,101		(252	)
Mortgage Backed Securities - Commercial		75,081		(404	)		4,249		(144	)		79,330		(548	)

Total Short-Term Investments	$	503,420	$	(1,686	)	$	10,841	$	(173	)	$	514,261	$	(1,859	)

The amortized cost and fair value of cash equivalents, short-term investments, and restricted cash and investments with contractual maturities are as follows as of March 30, 2014:


	Cost		Estimated Fair Value
	(in thousands)
Due in one year or less	$	1,316,589	$	1,317,140
Due after one year through five years		1,035,559		1,036,852
Due in more than five years		290,039		289,412

	$	2,642,187	$	2,643,404

Management has the ability, if necessary, to liquidate its cash equivalents and short-term investments in order to meet the Company’s liquidity needs in the next 12 months. Accordingly, those investments with contractual maturities greater than one year from the date of purchase nonetheless are classified as short-term on the accompanying Consolidated Balance Sheets.

Derivative Instruments and Hedging

The Company carries derivative financial instruments (“derivatives”) on its Consolidated Balance Sheets at their fair values. The Company enters into foreign currency forward contracts with financial institutions with the primary objective of reducing volatility of earnings and cash flows related to foreign currency exchange rate fluctuations. The counterparties to these forward contracts are large global financial institutions that the Company believes are creditworthy, and therefore, we do not consider the risk of counterparty nonperformance to be material.

Cash Flow Hedges

The Company’s financial position is routinely subjected to market risk associated with foreign currency exchange rate fluctuations on non-U.S. dollar transactions or cash flows, primarily from Japanese yen-denominated revenues and euro-denominated expenses. The Company’s policy is to mitigate the foreign exchange risk arising from the fluctuations in the value of these non-U.S. dollar denominated transactions or cash flows through a foreign currency cash flow hedging program, using forward contracts that generally expire within 12 months and no later than 24 months. These foreign currency forward contracts are designated as cash flow hedges and are carried on the Company’s balance sheet at fair value with the effective portion of the contracts’ gains or losses included in accumulated other comprehensive income (loss) and subsequently recognized in revenue/expense in the same period the hedged items are recognized.

At inception and at each quarter end, hedges are tested prospectively and retrospectively for effectiveness using regression analysis. Changes in the fair value of the forward contracts due to changes in time value are excluded from the assessment of effectiveness and are recognized in revenue or expense in the current period. The change in time value related to these contracts was not material for all reported periods. To qualify for hedge accounting, the hedge relationship must meet criteria relating both to the derivative instrument and the hedged item. These criteria include identification of the hedging instrument, the hedged item, the nature of the risk being hedged and how the hedging instrument’s effectiveness in offsetting the exposure to changes in the hedged item’s fair value or cash flows will be measured. There were no gains or losses during the three and nine months ended March 30, 2014 or March 31, 2013 associated with ineffectiveness or forecasted transactions that failed to occur.

To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge and the hedges must be tested to demonstrate an expectation of providing highly effective offsetting changes to future cash flows on hedged transactions. When derivative instruments are designated and qualify as effective cash flow hedges, the Company recognizes effective changes in the fair value of the hedging instrument within accumulated other comprehensive income (loss) until the hedged exposure is realized. Consequently, with the exception of excluded time value and hedge ineffectiveness recognized, the Company’s results of operations are not subject to fluctuation as a result of changes in the fair value of the derivative instruments. If hedges are not highly effective or if the Company does not believe that the underlying hedged forecasted transactions will occur, the Company may not be able to account for its derivative instruments as cash flow hedges. If this were to occur, future changes in the fair values of the Company’s derivative instruments would be recognized in earnings. Additionally, related amounts previously recorded in other comprehensive income would be reclassified to income immediately. At March 30, 2014, the Company had gains of $1.4 million accumulated in other comprehensive income, which it expects to reclassify from other comprehensive income into earnings over the next 12 months.

Balance Sheet Hedges

The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency denominated monetary assets and liabilities, primarily third party accounts receivables, accounts payables and intercompany receivables and payables. These forward contracts are not designated for hedge accounting treatment. Therefore, the change in fair value of these derivatives is recorded as a component of other income (expense) and offsets the change in fair value of the foreign currency denominated assets and liabilities, which are also recorded in other income (expense).

As of March 30, 2014, the Company had the following outstanding foreign currency forward contracts that were entered into under its cash flow and balance sheet hedge program:


	Derivatives Designated as				Derivatives Not Designated as
	Hedging Instruments:				Hedging Instruments:
	(in thousands)
Foreign Currency Forward Contracts
	Buy Contracts		Sell Contracts		Buy Contracts		Sell Contracts
Japanese Yen	$	—	$	123,282	$	—	$	65,959
Swiss Franc						7,496		—
Euro		60,487		—		—		8,901
Korean Won		—		—		36,386		—
Taiwan Dollar		—		—		188,583		65,899

	$	60,487	$	123,282	$	232,465	$	140,759

The fair value of derivative instruments in the Company’s Consolidated Balance Sheets as of March 30, 2014 and June 30, 2013 were as follows:

March 30, 2014

June 30, 2013

Fair Value of Derivative Instruments

Asset Derivatives

Liability Derivatives

Asset Derivatives

Liability Derivatives

Balance Sheet
Location

Fair Value

Balance Sheet
Location

Fair Value

Balance Sheet
Location

Fair Value

Balance Sheet
Location

Fair
Value

(in thousands)

Derivatives designated as hedging instruments:

Foreign exchange forward contracts

Prepaid expense and other assets

2,297

Accrued liabilities

619

Prepaid expense and other assets

4,858

Accrued
liabilities

1,577

Derivatives not designated as hedging instruments:

Foreign exchange forward contracts

Prepaid expense and other assets

190

Accrued liabilities

571

Prepaid expense and other assets

Accrued
liabilities

Total derivatives

2,487

1,190

4,929

1,620

Under the master netting agreements with the respective counterparties to the Company’s foreign exchange contracts, subject to applicable requirements, the Company is allowed to net settle transactions of the same currency with a single net amount payable by one party to the other. However, the Company has elected to present the derivative assets and derivative liabilities on a gross basis in its balance sheet. As of March 30, 2014, the potential effect of netting the above foreign exchange contracts would be an offset to assets and liabilities by $0.7 million, resulting in a net derivative asset of $1.3 million. As of June 30, 2013, the potential effect of netting the above foreign exchange contracts was an offset to both assets and liabilities by $1.6 million, resulting in a net derivative asset of $3.3 million. The Company is not required to pledge, nor is the Company entitled to receive, cash collateral for these derivative transactions.

The effect of derivative instruments designated as cash flow hedges on the Company’s Condensed Consolidated Statements of Operations, including accumulated other comprehensive income (“AOCI”) was as follows:


	Three Months Ended March 30, 2014								Nine Months Ended March 30, 2014
	Effective Portion					Ineffective Portion and Amount Excluded from Effectiveness Testing			Effective Portion					Ineffective Portion and Amount Excluded from Effectiveness Testing
Location of Gain (Loss) Recognized in or Reclassified into Income	Gain (Loss) Recognized in AOCI			Gain Reclassified from AOCI into Income		Gain (Loss) Recognized in Income			Gain Recognized in AOCI		Gain Reclassified from AOCI into Income			Gain (Loss) Recognized in Income
	(in thousands)								(in thousands)
Revenue	$	(621	)	$	2,787	$	54		$	7,483	$	8,947		$	232
Cost of goods sold		307			646		(10	)		1,717		1,764			(66	)
Selling, general, and administrative		112			291		(5	)		667		800			(29	)
Other income (expense)		—			—		—			—		—			—

	$	(202	)	$	3,724	$	39		$	9,867	$	11,511		$	137


	Three Months Ended March 31, 2013								Nine Months Ended March 31, 2013
	Effective Portion					Ineffective Portion and Amount Excluded from Effectiveness Testing			Effective Portion					Ineffective Portion and Amount Excluded from Effectiveness Testing
Location of Gain (Loss) Recognized in or Reclassified into Income	Gain (Loss) Recognized in AOCI			Gain Reclassified from AOCI into Income		Gain (Loss) Recognized in Income			Gain Recognized in AOCI		Gain (Loss) Reclassified from AOCI into Income			Gain (Loss) Recognized in Income
	(in thousands)								(in thousands)
Revenue	$	9,454		$	3,850	$	78		$	8,159	$	4,574		$	274
Cost of goods sold		(563	)		1,194		(44	)		1,332		(1,069	)		(208	)
Selling, general, and administrative		(491	)		345		(20	)		537		(405	)		(100	)
Other income (expense)		—			—		—			—		—			(8	)

	$	8,400		$	5,389	$	14		$	10,028	$	3,100		$	(42	)

The effect of derivative instruments not designated as cash flow hedges on the Company’s Condensed Consolidated Statements of Operations was as follows:

Three Months Ended

Nine Months Ended

March 30, 2014

March 31, 2013

March 30, 2014

March 31, 2013

Derivatives Not Designated

as Hedging Instruments:

Location of Gain (Loss) Recognized in
Income

Loss
Recognized
in Income

Gain
Recognized
in Income

(in thousands)

Foreign Exchange Contracts

Other income (expense)

(6,527

)

2,061

4,512

2,347

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, short-term investments, restricted cash and investments, trade accounts receivable, and derivative financial instruments used in hedging activities. Cash is placed on deposit at large global financial institutions. Such deposits may be in excess of insured limits. Management believes that the financial institutions that hold the Company’s cash are creditworthy and, accordingly, minimal credit risk exists with respect to these balances.

The Company’s overall portfolio of available-for-sale securities must maintain an average minimum rating of “AA-” or “Aa3” as rated by Standard and Poor’s or Moody’s Investor Services, respectively. To ensure diversification and minimize concentration, the Company’s policy limits the amount of credit exposure with any one financial institution or commercial issuer.

The Company is exposed to credit losses in the event of nonperformance by counterparties on the foreign currency forward hedge contracts and on structured share repurchase arrangements. These counterparties are large global financial institutions and, to date, no such counterparty has failed to meet its financial obligations to the Company.

Credit risk evaluations, including trade references, bank references and Dun & Bradstreet ratings, are performed on all new customers and the Company monitors its customers’ financial statements and payment performance. In general, the Company does not require collateral on sales.

INVENTORIES

9 Months Ended

Mar. 30, 2014

INVENTORIES

NOTE 5 — INVENTORIES

Inventories are stated at the lower of cost (first-in, first-out method) or market. Shipments to Japanese customers, to whom title does not transfer until customer acceptance, are classified as finished goods inventory and carried at cost until title transfers. Inventories consist of the following:


	March 30,		June 30,
	2014		2013
	(in thousands)
Raw materials	$	440,772	$	312,484
Work-in-process		114,890		101,530
Finished goods		161,694		145,303

	$	717,356	$	559,317

PROPERTY AND EQUIPMENT, NET

9 Months Ended

Mar. 30, 2014

PROPERTY AND EQUIPMENT, NET

NOTE 6 — PROPERTY AND EQUIPMENT, NET

Property and equipment, net, consists of the following:


	March 30,			June 30,
	2014			2013
	(in thousands)
Manufacturing, engineering and office equipment	$	590,505		$	521,047
Computer equipment and software		128,753			120,144
Land		55,951			65,360
Buildings		207,537			249,126
Leasehold improvements		79,152			76,225
Furniture and fixtures		24,824			21,110

		1,086,722			1,053,012
Less: accumulated depreciation and amortization		(534,131	)		(449,102	)

	$	552,591		$	603,910

During the nine months ended March 30, 2014, the Company sold or reclassified to assets held-for-sale property and equipment with a net book value of $69 million as a result of facility consolidation. These assets consisted primarily of buildings and land, resulting in the decreases to those asset categories in the table above.

GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Mar. 30, 2014

GOODWILL AND INTANGIBLE ASSETS

NOTE 7 — GOODWILL AND INTANGIBLE ASSETS

Goodwill

There was no significant change in the goodwill balance during the nine months ended March 30, 2014. Of the $1.5 billion goodwill balance as of March 30, 2014, $61 million is tax deductible and the remaining balance is not tax deductible due to purchase accounting and applicable foreign law.

Goodwill is assessed at least annually for impairment. The Company did not record impairments of goodwill during the three or nine months ended March 30, 2014 or March 31, 2013.

Intangible Assets

The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of March 30, 2014:


	Gross		Accumulated Amortization			Net		Weighted-Average Useful Life
	(in thousands)							(years)
Customer relationships	$	625,072	$	(156,121	)	$	468,951		9.01
Existing technology		662,357		(207,981	)		454,376		6.96
Patents		32,053		(23,887	)		8,166		6.09
Other intangible assets		35,216		(35,216	)		—		4.10

Intangible assets subject to amortization		1,354,698		(423,205	)		931,493
In process research and development		11,000					11,000
Development rights		9,100					9,100

Intangible assets not subject to amortization		20,100					20,100

Total intangible assets	$	1,374,798	$	(423,205	)	$	951,593

The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of June 30, 2013 (in thousands, except years):


	Gross		Accumulated Amortization			Net		Weighted-Average Useful Life
	(in thousands)							(years)
Customer relationships	$	624,686	$	(103,519	)	$	521,167		9.01
Existing technology		653,628		(139,894	)		513,734		6.97
Patents		32,053		(22,036	)		10,017		6.09
Backlog		10,000		(10,000	)		—		1.00
Other intangible assets		35,216		(34,889	)		327		4.10

Intangible assets subject to amortization		1,355,583		(310,338	)		1,045,245
In process research and development		20,000					20,000
Development rights		9,100					9,100

Intangible assets not subject to amortization		29,100					29,100

Total intangible assets	$	1,384,683	$	(310,338	)	$	1,074,345

The Company recognized $40.4 million and $45.0 million in intangible asset amortization expense during the three months ended March 30, 2014 and March 31, 2013, respectively. The Company recognized $122.9 million and $134.3 million in intangible asset amortization expense during the nine months ended March 30, 2014 and March 31, 2013, respectively. The Company recognized a $4.0 million impairment of in process research and development during the three and nine months ended March 31, 2014 due to the cancellation of a project.

The estimated future amortization expense of purchased intangible assets as of March 30, 2014 is as follows:


Fiscal Year	Amount
	(in thousands)
2014 (3 months)	$	39,842
2015		159,718
2016		157,510
2017		155,790
2018		154,625
Thereafter		264,008

	$	931,493

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

9 Months Ended

Mar. 30, 2014

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

NOTE 8 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consist of the following:


	March 30,		June 30,
	2014		2013
	(in thousands)
Accrued compensation	$	283,594	$	254,795
Warranty reserves		71,489		52,252
Income and other taxes payable		51,178		39,420
Other		109,243		118,061

	$	515,504	$	464,528

OTHER EXPENSE, NET

9 Months Ended

Mar. 30, 2014

OTHER EXPENSE, NET

NOTE 9 — OTHER EXPENSE, NET

The significant components of other expense, net, are as follows:


	Three Months Ended						Nine Months Ended
	March 30,			March 31,			March 30,			March 31,
	2014			2013			2014			2013
	(in thousands)
Interest income	$	3,110		$	3,235		$	8,661		$	11,411
Interest expense		(15,621	)		(15,175	)		(46,220	)		(45,294	)
Gains on deferred compensation plan related assets		3,137			3,112			8,534			7,087
Foreign exchange gains (losses)		(85	)		(1,294	)		(181	)		(4,936	)
Other, net		(396	)		(5,712	)		1,252			(7,430	)

	$	(9,855	)	$	(15,834	)	$	(27,954	)	$	(39,162	)

INCOME TAX EXPENSE

9 Months Ended

Mar. 30, 2014

INCOME TAX EXPENSE

NOTE 10 — INCOME TAX EXPENSE

The Company recorded an income tax expense of $17.7 million and $35.0 million for the three and nine months ended March 30, 2014, respectively, which yielded an effective tax rate for the three and nine months ended March 30, 2014 of approximately 9.7% and 8.1%, respectively. The difference between the U.S. federal statutory tax rate of 35% and the Company’s effective tax rate for the three and nine months ended March 30, 2014 is primarily due to the geographic mix of income and the recognition of previously unrecognized tax benefits due to lapse of statutes of limitation, offset by the tax effect of non-deductible stock-based compensation and unrecognized tax benefits due to uncertain tax positions.

NET INCOME PER SHARE

9 Months Ended

Mar. 30, 2014

NET INCOME PER SHARE

NOTE 11 — NET INCOME PER SHARE

Basic net income per share is computed by dividing net income by the weighted-average number of shares of Common Stock outstanding during the period. Diluted net income per share is computed using the treasury stock method, for dilutive stock options, RSUs, and convertible notes. Dilutive shares outstanding include only the effect of the 2041 Notes. The following table reconciles the numerators and denominators of the basic and diluted computations for net income per share.


	Three Months Ended				Nine Months Ended
	March 30,		March 31,		March 30,		March 31,
	2014		2013		2014		2013
	(in thousands, except per share data)
Numerator:
Net income	$	164,396	$	18,996	$	398,894	$	28,172

Denominator:
Basic average shares outstanding		162,238		163,034		161,904		171,016
Effect of potential dilutive securities:
Employee stock plans		2,641		2,729		2,810		2,390
Convertible notes		6,757		2,741		6,337		900

Diluted average shares outstanding		171,636		168,504		171,051		174,306

Net income per share - basic	$	1.01	$	0.12	$	2.46	$	0.16

Net income per share - diluted	$	0.96	$	0.11	$	2.33	$	0.16

For purposes of computing diluted net income per share, weighted-average common shares do not include potentially dilutive securities that are anti-dilutive under the treasury stock method. The following potentially dilutive securities were excluded:

Three Months Ended

Nine Months Ended

March 30,

March 31,

March 30,

March 31,

2014

2013

2014

2013

(in thousands)

Number of potential dilutive securities excluded

298

567

Diluted shares outstanding do not include any effect resulting from warrants, assumed conversion of the notes, or note hedges associated with the Company’s 2016 or 2018 Notes (as described in Note 13) as their impact would have been anti-dilutive.

ACCUMULATED OTHER COMPREHENSIVE LOSS

9 Months Ended

Mar. 30, 2014

ACCUMULATED OTHER COMPREHENSIVE LOSS

NOTE 12 — ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of accumulated other comprehensive income (loss), net of tax at the end of the period, as well as the activity during the period, were as follows:


	Accumulated foreign currency translation adjustment			Accumulated unrealized holding gain (loss) on cash flow hedges			Accumulated unrealized holding gain (loss) on available-for-sale investments			Accumulated unrealized components of defined benefit plans			Total
	(in thousands)
Balance as of June 30, 2013	$	(17,178	)	$	2,822		$	(15	)	$	(14,322	)	$	(28,693	)
Other comprehensive income before reclassifications		1,680			8,632			962			534			11,808
Gains reclassified from accumulated other comprehensive income to net income		—			(10,066	)⁽¹⁾		(120	)⁽²⁾		—			(10,186	)

Net current-period other comprehensive income	$	1,680		$	(1,434	)	$	842		$	534		$	1,622

Balance as of March 30, 2014	$	(15,498	)	$	1,388		$	827		$	(13,788	)	$	(27,071	)

(1)	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in revenue: $7,961, cost of goods sold: $1,505 and selling, general and administrative expenses: $600.

(2)	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in other expense, net.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

LONG-TERM DEBT AND OTHER BORROWINGS

9 Months Ended

Mar. 30, 2014

LONG-TERM DEBT AND OTHER BORROWINGS

NOTE 13 — LONG-TERM DEBT AND OTHER BORROWINGS

The following table reflects the carrying value of the Company’s convertible senior notes and other long-term debt as of March 30, 2014 and June 30, 2013:


	March 30,			June 30,
	2014			2013
	*(in millions)*
0.50% Notes due 2016	$	450.0		$	450.0
Less: Unamortized interest discount		(34.3	)		(45.7	)

Net carrying amount of 0.50% Notes due 2016		415.7			404.3

1.25% Notes due 2018		450.0			450.0
Less: Unamortized interest discount		(66.3	)		(76.9	)

Net carrying amount of 1.25% Notes due 2018		383.7			373.1

2.625% Notes due 2041		699.9			699.9
Less: Unamortized interest discount		(184.2	)		(186.9	)

Net carrying amount of 2.625% Notes due 2041		515.7			513.0

Total debt		1,315.1			1,290.4

Less: current portion of debt		(515.7	)		(513.0	)

Long-term debt	$	799.4		$	777.4

Convertible Senior Notes

In May 2011, the Company issued and sold $450.0 million in aggregate principal amount of 0.50% Convertible Senior Notes due May 2016 (the “2016 Notes”) at par. At the same time, the Company issued and sold $450.0 million in aggregate principal amount of 1.25% Convertible Senior Notes due May 2018 (the “2018 Notes”) at par. The 2016 Notes and the 2018 Notes may be converted, under certain circumstances, based on an initial conversion rate of 15.8687 shares of Common Stock per $1,000 principal amount of notes (which represents an initial conversion price of approximately $63.02 per share of Common Stock).The net proceeds to the Company from the sale of the 2016 Notes and the 2018 Notes were $835.5 million. The Company pays cash interest at an annual rate of 0.5% and 1.25%, respectively, on the 2016 Notes and the 2018 Notes, on a semi-annual basis on May 15 and November 15 of each year.

In June 2012, with the acquisition of Novellus, the Company assumed $700.0 million in aggregate principal amount of 2.625% Convertible Senior Notes due May 2041 (the “2041 Notes,” and collectively with the 2016 Notes and the 2018 Notes, the “Notes”). The 2041 Notes may be converted, under certain circumstances, based on an initial conversion rate of 28.4781 shares of Common Stock per $1,000 principal amount of notes (which represents an initial conversion price of approximately $35.11 per share of Common Stock). The Company pays cash interest at an annual rate of 2.625%, on a semi-annual basis on May 15 and November 15 of each year. The 2041 Notes also have a contingent interest payment provision that may require the Company to pay additional interest based on certain thresholds, beginning with the semi-annual interest payment commencing on May 15, 2021, and upon the occurrence of certain events, as outlined in the indenture governing the 2041 Notes. The maximum amount of the contingent interest will accrue at a rate of 2.1% per annum, excluding any potential impact from dividends deemed payable to holders of the 2041 Notes. The contingent interest payment provision has been identified as an embedded derivative, to be accounted for separately, and is recorded at fair value at the end of each reporting period in other non-current liabilities, with any gains and losses recorded in interest expense, within the Condensed Consolidated Statements of Operations.

The Company separately accounts for the liability and equity components of the Notes. The initial debt components of the 2016 Notes, the 2018 Notes, and the 2041 Notes were valued at $373.8 million, $345.1 million, and $509.5 million, respectively, based on the present value of the future cash flows using discount rates of 4.29%, 5.27%, and 4.28%, respectively, the Company’s borrowing rate at the date of the issuance or assumption for similar debt instruments without the conversion feature. The carrying values of the equity components of the 2016 Notes, the 2018 Notes, and the 2041 Notes were $76.2 million, $104.9 million, and $328.1 million, respectively as of March 30, 2014. The effective interest rates on the liability components of the 2016 Notes, the 2018 Notes, and the 2041 Notes for the three and nine months ended March 30, 2014 were 4.29%, 5.27%, and 4.28%, respectively. The following table presents the amount of interest cost recognized relating to both the contractual interest coupon and amortization of the discount on the liability component of the Notes during the three and nine months ended March 30, 2014 and March 31, 2013.


	Three Months Ended				Nine Months Ended
	March 30,		March 31,		March 30,		March 31,
	2014		2013		2014		2013
	*(in millions)*
Contractual interest coupon	$	6.6	$	6.6		19.7		19.7
Amortization of interest discount		8.3		7.9		24.7		23.5
Amortization of issuance costs		0.6		0.6		1.8		1.8

Total interest cost recognized	$	15.5	$	15.1	$	46.2	$	45.0

The remaining bond discount of the 2016 Notes, the 2018 Notes, and the 2041 Notes of $34.3 million, $66.3 million, and $184.2 million, respectively, as of March 30, 2014 will be amortized over their respective remaining lives of approximately 2.1 years, 4.1 years, and 27.1 years. As of March 30, 2014, the if-converted value of the 2016 Notes and 2018 Notes did not exceed the aggregate principal amount. As of March 30, 2014, the if-converted value of the 2041 Notes exceeded the aggregate principal amount by $386.3 million.

Convertible Note Hedges and Warrants

Concurrently with the issuance of the 2016 Notes and the 2018 Notes, the Company purchased convertible note hedges and sold warrants. The separate convertible note hedge and warrant transactions are collectively structured to reduce the potential future economic dilution associated with the conversion of the 2016 Notes and the 2018 Notes and to increase the effective initial conversion price to $71.34 and $76.10 per share, respectively. Each of these components is discussed below.

Concurrent with the issuance of the 2016 Notes, the Company sold warrants to purchase up to approximately 7.1 million shares of Common Stock at an exercise price of $71.34 per share. The warrants expire on a series of dates between August 15, 2016 and October 21, 2016. At expiration, the Company may, at its option, elect to settle the warrants on a net share basis. As of March 30, 2014, the warrants had not been exercised and remained outstanding. In addition, counterparties agreed to sell to the Company up to approximately 7.1 million shares of Common Stock, which is the number of shares initially issuable upon conversion of the 2016 Notes in full, at a price of $63.02 per share. The convertible note hedge transaction will be settled in net shares and will terminate upon the earlier of the maturity date of the 2016 Notes or the first day none of the 2016 Notes remains outstanding due to conversion or otherwise. Settlement of the convertible note hedge in net shares, based on the number of shares issued upon conversion of the 2016 Notes, on the expiration date would result in the Company receiving net shares equivalent to the number of shares issuable by the Company upon conversion of the 2016 Notes.

Concurrent with the issuance of the 2018 Notes, the Company sold warrants to purchase up to approximately 7.1 million shares of Common Stock at an exercise price of $76.10 per share. The warrants expire on a series of dates between August 15, 2018 and October 23, 2018. At expiration, the Company may, at its option, elect to settle the warrants on a net share basis. As of March 30, 2014, the warrants had not been exercised and remained outstanding. In addition, counterparties agreed to sell to the Company up to approximately 7.1 million shares of Common Stock, which is the number of shares initially issuable upon conversion of the 2018 Notes in full, at a price of $63.02 per share. The convertible note hedge transaction will be settled in net shares and will terminate upon the earlier of the maturity date of the 2018 Notes or the first day none of the 2018 Notes remains outstanding due to conversion or otherwise. Settlement of the convertible note hedge in net shares, based on the number of shares issued upon conversion of the 2018 Notes, on the expiration date would result in the Company receiving net shares equivalent to the number of shares issuable by the Company upon conversion of the 2018 Notes.

Conversion Period

During the fiscal quarters ended June 30, 2013, December 29, 2013 and March 30, 2014 the market value of the Common Stock was greater than or equal to 130% of the 2041 Note conversion price for 20 or more trading days of the 30 consecutive trading days preceding the quarter end. As a result, the 2041 Notes became convertible at the option of the holder anytime during the fiscal quarters ending December 29, 2013 and continue to be convertible through June 29, 2014 (the “June 2014 quarter”). However, there were no conversions of the 2041 Notes during the March 2014 quarter or the June 2014 quarter as of May 5, 2014.

As a result of the open conversion period, the carrying amount of the 2041 Notes was classified in current liabilities in the Company’s Consolidated Balance Sheets as of March 30, 2014 and June 30, 2013. The excess of the amount of cash payable, if converted, over the carrying amount of the 2041 Notes was classified as temporary equity as of March 30, 2014 and June 30, 2013. Upon closure of a conversion period, all 2041 Notes not converted will be reclassified back to noncurrent liabilities and the temporary equity is reclassified to permanent equity.

Fair Value of Notes

As of March 30, 2014, the face values of the 2016 Notes, the 2018 Notes, and the 2041 Notes were $450.0 million, $450.0 million, and $699.9 million, respectively. As of March 30, 2014, the fair values of the 2016 Notes, the 2018 Notes, and the 2041 Notes, which includes the debt and equity components, were approximately $518.6 million, $558.4 million, and $1,196.9 million, respectively, based on quoted market prices (Level 1 inputs within the fair value hierarchy).

Revolving Credit Facility

On March 12, 2014 the Company entered into a $300 million revolving unsecured credit facility with a syndicate of lenders that matures on March 12, 2019. The facility includes an option for the Company to, subject to certain requirements, request an increase in the facility of up to an additional $200 million, for a potential total commitment of $500 million. Proceeds from the credit facility can be used for general corporate purposes.

Interest on amounts borrowed under the credit facility is, at the Company’s option, based on (i) a base rate, defined as the greatest of (a) prime rate, (b) Federal Funds rate plus 0.5%, or (c) one-month LIBOR plus 1.0%, plus a spread of 0.0% to 0.5%, or (ii) LIBOR plus a spread of 0.9% to 1.5%, in each case the applicable spread is determined based on the rating of the Company’s non-credit enhanced, senior unsecured long-term debt. Principal, and any accrued and unpaid interest, is due and payable upon maturity. Additionally, the Company will pay the lenders a quarterly commitment fee that varies based on the Company’s rating described above. The credit facility contains certain restrictive covenants including maintaining a total consolidated indebtedness to consolidated capitalization ratio of no more than 0.5 to 1.0 and maintaining unrestricted or unencumbered cash and investments of no less than $1.0 billion. As of March 30, 2014, we had no borrowings outstanding under the credit facility and were in compliance with all financial covenants.

COMMITMENTS

9 Months Ended

Mar. 30, 2014

COMMITMENTS

NOTE 14 — COMMITMENTS

Operating Leases and Related Guarantees

The Company leases certain of its administrative, research and development (“R&D”) and manufacturing facilities, regional sales/service offices and certain equipment under non-cancelable operating leases. Certain of the Company’s facility leases for buildings located at its Fremont, California headquarters and certain other facility leases provide the Company with options to extend the leases for additional periods or to purchase the facilities. Certain of the Company’s facility leases provide for periodic rent increases based on the general rate of inflation.

On December 31, 2013, the Company extinguished its two operating leases regarding certain improved properties in Livermore, California and its four amended and restated operating leases regarding certain improved properties in Fremont, California and entered into six amended operating leases (the “Operating Leases”) regarding certain improved properties at the Company’s headquarters in Fremont, California and certain other improved properties in Livermore, California.

The Operating Leases have a term of approximately seven years ending on December 31, 2020. The Company may, at its discretion and with 30 days’ notice, elect to purchase the property that is the subject of the Operating Leases for an amount approximating the sum required to pay the amount of the lessor’s investment in the property and any accrued but unpaid rent.

As of March 30, 2014, the Company was required, pursuant to the terms of the Operating Leases, to maintain cash collateral in an aggregate of approximately $132.5 million in separate interest-bearing accounts and marketable securities collateral in an aggregate of approximately $6.1 million as security for the Company’s obligations under the Operating Leases. These amounts are recorded as restricted cash and investments in the Company’s Consolidated Balance Sheet as of March 30, 2014.

During the term of the Operating Leases and when the terms of the Operating Leases expire, the property subject to those Operating Leases may be remarketed. The Company has guaranteed to the lessor that each property will have a certain minimum residual value. The aggregate guarantee made by the Company under the Operating Leases is generally no more than approximately $191.2 million; however, under certain default circumstances, the guarantee with regard to an Operating Lease may be 100% of the lessor’s aggregate investment in the applicable property, which in no case will exceed $220.0 million, in the aggregate.

Other Guarantees

The Company has issued certain indemnifications to its lessors for taxes and general liability under some of its agreements. The Company has entered into certain insurance contracts that may limit its exposure to such indemnifications. As of March 30, 2014, the Company had not recorded any liability in connection with these indemnifications, as it does not believe, based on information available, that it is probable that any amounts will be paid under these guarantees.

Generally, the Company indemnifies, under pre-determined conditions and limitations, its customers for infringement of third-party intellectual property rights by the Company’s products or services. The Company seeks to limit its liability for such indemnity to an amount not to exceed the sales price of the products or services subject to its indemnification obligations. The Company does not believe, based on information available, that it is probable that any material amounts will be paid under these guarantees.

The Company provides guarantees and standby letters of credit to certain parties as required for certain transactions initiated during the ordinary course of business. As of March 30, 2014, the maximum potential amount of future payments that we could be required to make under these arrangements and letters of credit was $20.9 million. We do not believe, based on historical experience and information currently available, that it is probable that any amounts will be required to be paid.

Warranties

The Company provides standard warranties on its systems. The liability amount is based on actual historical warranty spending activity by type of system, customer, and geographic region, modified for any known differences such as the impact of system reliability improvements.

Changes in the Company’s product warranty reserves were as follows:


	Three Months Ended						Nine Months Ended
	March 30,			March 31,			March 30,			March 31,
	2014			2013			2014			2013
	(in thousands)
Balance at beginning of period	$	67,413		$	62,922		$	58,078		$	70,161
Warranties issued during the period		25,106			18,829			67,405			53,377
Settlements made during the period		(19,686	)		(27,101	)		(52,958	)		(72,960	)
Changes in liability for pre-existing warranties		(258	)		90			50			4,162

Balance at end of period	$	72,575		$	54,740		$	72,575		$	54,740

RESTRUCTURING AND IMPAIRMENTS

9 Months Ended

Mar. 30, 2014

RESTRUCTURING AND IMPAIRMENTS

NOTE 15 — RESTRUCTURING AND IMPAIRMENTS

From time to time, the Company initiates restructuring activities to appropriately align its cost structure relative to prevailing economic and industry conditions and associated customer demand as well as in connection with certain acquisitions. Costs associated with restructuring actions can include termination benefits and related charges in addition to facility closure, contract termination and other related activities.

Accounting for restructuring activities, as compared to regular operating cost management activities, requires an evaluation of formally committed and approved plans. Restructuring activities have comparatively greater strategic significance and materiality and may involve exit activities, whereas regular cost containment activities are more tactical in nature and are rarely characterized by formal and integrated action plans or exiting a particular product, facility, or service.

March 2009 Plan

Beginning in the March 2009 quarter, the Company incurred restructuring expenses designed to align the Company’s cost structure with its outlook for the economic environment and business opportunities. During the March 2014 quarter, the Company entered into the Operating Leases and de-recognized the remaining liability associated with the residual value guarantee. See Note 14 to the Condensed Consolidated Financial Statements for additional information regarding residual value guarantees.

Acquired Restructuring Liabilities

In addition to restructuring plans initiated by the Company, a restructuring liability related to future rent obligations on unoccupied facilities was assumed in the Novellus acquisition. The associated liability balance of $10.3 million, as of March 30, 2014, is expected to be paid by the end of fiscal year 2017.

STOCK REPURCHASE PROGRAM

9 Months Ended

Mar. 30, 2014

STOCK REPURCHASE PROGRAM

NOTE 16 — STOCK REPURCHASE PROGRAM

On April 22, 2013, the Board of Directors authorized the repurchase of up to $250 million of Common Stock. In addition, on April 29, 2014, the Board of Directors authorized the repurchase of up to $850 million of Common Stock, which includes the remaining value available under the Company’s prior authorization. These repurchases can be conducted on the open market or as private purchases and may include the use of derivative contracts with large financial institutions, in all cases subject to compliance with applicable law. Repurchases will be funded using the Company’s on-shore cash and on-shore cash generation. This repurchase program has no termination date and may be suspended or discontinued at any time.

Repurchases under the 2013 repurchase program were as follows during the periods indicated:


Period	Total Number of Shares Repurchased		Total Cost of Repurchase		Average Price Paid Per Share*		Amount Available Under Repurchase Program
	(in thousands, except per share data)
Available balance as of June 30, 2013							$	250,000
Quarter ended September 29, 2013		1,935	$	96,462	$	48.06	$	153,538
Quarter ended December 29, 2013		762	$	39,800	$	52.20	$	113,738
Quarter ended March 30, 2014		930	$	49,414	$	53.13	$	64,324

Average price paid per share excludes accelerated share repurchases for which cost was incurred during the September 2013 quarter, but that did not settle until the December 2013 quarter. See Collared Accelerated Share Repurchases section below for details regarding average price associated with these transactions.

In addition to shares repurchased under the Board-authorized repurchase program shown above, during the nine months ended March 30, 2014, the Company acquired 468,585 shares at a total cost of $23.9 million, which the Company withheld through net share settlements to cover minimum tax withholding obligations upon the vesting of restricted stock unit awards granted under the Company’s equity compensation plans. The shares retained by the Company through these net share settlements are not a part of the Board-authorized repurchase program but instead are authorized under the Company’s equity compensation plans.

As part of its share repurchase program, the Company may from time-to-time enter into structured share repurchase arrangements with financial institutions using general corporate funds. Such arrangements entered into or settled during the nine months ended March 30, 2014 included the following:

Collared Accelerated Share Repurchases

During the nine months ended March 30, 2014, the Company entered into a collared accelerated share repurchase (“ASR”) transaction under a master repurchase arrangement. Under the ASR, the Company made an up-front cash payment of $75 million, in exchange for an initial delivery of 1.2 million shares of its Common Stock and a subsequent delivery of 0.3 million shares following the initial hedge period.

The number of shares to ultimately be repurchased by the Company is based generally on the volume-weighted average price (“VWAP”) of the Common Stock during the term of the ASR minus a pre-determined discount set at inception of the ASR, subject to collar provisions that provide a minimum and maximum number of shares that the Company could repurchase under the agreements. The minimum and maximum thresholds for the transaction were established based on the average of the VWAP prices for the Common Stock during an initial hedge period. The ASR was scheduled to end at any time after September 27, 2013 and on or before November 27, 2013. At the conclusion of the ASR, the Company may receive additional shares based on the VWAP of the Common Stock during the term of the agreement minus the pre-determined fixed discount, however, the total number of shares received under the ASR would not exceed the maximum of 1.7 million shares.

The counterparty designated October 28, 2013 as the termination date, at which time the Company settled the ASR. No additional shares were received at final settlement, which represented a weighted-average share price of approximately $50.40 for the transaction period.

The Company accounted for the ASR as two separate transactions: (a) as shares of Common Stock acquired in a treasury stock transaction recorded on the acquisition date and (b) as a forward contract indexed to the Company’s own Common Stock and classified in stockholders’ equity. As such, the Company accounted for the shares that it received under the ASR as a repurchase of its Common Stock for the purpose of calculating earnings per common share. The Company has determined that the forward contract indexed to the Common Stock met all of the applicable criteria for equity classification in accordance with the Derivatives and Hedging topic of the FASB Accounting Standards Codification, and, therefore, the ASR was not accounted for as a derivative instrument. As of March 30, 2014, the aggregate repurchase price of $75 million was reflected as Treasury stock, at cost, in the Consolidated Balance Sheet.

LEGAL PROCEEDINGS

9 Months Ended

Mar. 30, 2014

LEGAL PROCEEDINGS

NOTE 17 — LEGAL PROCEEDINGS

The Company is either a defendant or plaintiff in various actions that have arisen from time to time in the normal course of business, including intellectual property claims. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company believes that the amount of any such additional loss would be immaterial to the Company’s business, financial condition, and results of operations.

SUBSEQUENT EVENTS

9 Months Ended

Mar. 30, 2014

SUBSEQUENT EVENTS

NOTE 18 — SUBSEQUENT EVENTS

On April 29, 2014 our Board of Directors announced its plan to initiate a quarterly dividend, and declared a dividend of $0.18 per share payable on July 2, 2014 to stockholders of record as of June 11, 2014. Our ability to pay future quarterly dividends will be subject to capital availability and periodic determinations by our Board of Directors that cash dividends are in the best interest of our stockholders and are in compliance with all laws and agreements applicable to the declaration and payment of cash dividends by us.

In addition, on April 29, 2014 our Board of Directors has authorized the repurchase of up to $850 million of common stock, which includes the remaining value available under the Company’s prior authorization.

EQUITY-BASED COMPENSATION PLANS (Tables)

9 Months Ended

Mar. 30, 2014

Recognized Equity Based Compensation Expenses and Related Income Tax Benefit

The Company recognized the following equity-based compensation expense and related income tax benefit in the Condensed Consolidated Statements of Operations:


	Three Months Ended				Nine Months Ended
	March 30,		March 31,		March 30,		March 31,
	2014		2013		2014		2013
	(in millions)
Equity-based compensation expense	$	24.3	$	25.6	$	70.6	$	74.1
Income tax benefit related to equity-based compensation expense	$	4.1	$	4.3	$	11.7	$	13.3

Summary of Stock Option Activity

A summary of stock option activity under the Plans as of March 30, 2014 and changes during the nine months then ended is presented below:


Options	Shares (in thousands)			Weighted- Average Exercise Price		Weighted-Average Remaining Contractual Term (years)		Aggregate Intrinsic Value as of March 30, 2014 (in thousands)
Outstanding at June 30, 2013		2,571		$	26.87		4.48
Granted		166		$	51.76
Exercised		(1,065	)	$	24.50
Forfeited or expired		(1	)	$	29.71

Outstanding at March 30, 2014		1,671		$	30.86		4.78	$	39,501

Exercisable at March 30, 2014		1,066		$	24.62		3.86	$	31,840

Summary of Restricted Stock Units

A summary of the Company’s RSUs as of March 30, 2014 and changes during the nine months then ended is presented below:


	Shares			Average Grant-
Unvested Restricted Stock Units	(in thousands)			Date Fair Value
Unvested at June 30, 2013		4,842		$	39.32
Granted		1,376		$	49.47
Vested		(1,313	)	$	39.84
Forfeited		(181	)	$	39.48

Unvested at March 30, 2014		4,724		$	42.12

Schedule of ESPP Weighted-Average Assumptions


	Three Months Ended			Nine Months Ended
	March 30,			March 30,
	2014			2014
Expected term (years)		0.51			0.68
Expected stock price volatility		28.89	%		30.24	%
Risk-free interest rate		0.09	%		0.07	%

FINANCIAL INSTRUMENTS (Tables)

9 Months Ended

Mar. 30, 2014

Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis at March 30, 2014:


			Fair Value Measurement at March 30, 2014
			Quoted Prices in				Significant
			Active Markets for		Significant Other		Unobservable
			Identical Assets		Observable Inputs		Inputs
	Total		(Level 1)		(Level 2)		(Level 3)
	(In thousands)
Assets
Short-Term Investments
Money Market Funds	$	1,042,596	$	1,042,596	$	—	$	—
Municipal Notes and Bonds		248,949		—		248,949		—
US Treasury and Agencies		182,967		182,967		—		—
Government-Sponsored Enterprises		41,089		—		41,089		—
Foreign Government Bonds		34,988		—		34,988		—
Corporate Notes and Bonds		961,378		132,549		828,829		—
Mortgage Backed Securities - Residential		26,580		—		26,580		—
Mortgage Backed Securities - Commercial		104,857		—		104,857		—

Total Short-Term Investments	$	2,643,404	$	1,358,112	$	1,285,292	$	—
Mutual Funds		28,559		28,559		—		—
Derivative Assets		2,487		—		2,487		—

Total Assets	$	2,674,450	$	1,386,671	$	1,287,779	$	—

Liabilities
Derivative Liabilities	$	1,340	$	—	$	1,190	$	150

The following table sets forth the Company’s financial assets and liabilities measured at fair value on a recurring basis at June 30, 2013:


			Fair Value Measurement at June 30, 2013
	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(In thousands)
Assets
Short-Term Investments
Money Market Funds	$	725,311	$	725,311	$	—	$	—
Municipal Notes and Bonds		268,746		—		268,746		—
US Treasury and Agencies		155,293		155,293		—		—
Government-Sponsored Enterprises		54,805		—		54,805		—
Foreign Government Bond		24,972		—		24,972		—
Corporate Notes and Bonds		860,492		164,885		695,607		—
Mortgage Backed Securities - Residential		27,365		—		27,365		—
Mortgage Backed Securities - Commercial		107,958		—		107,958		—

Total Short-Term Investments	$	2,224,942	$	1,045,489	$	1,179,453	$	—
Equities		7,096		7,096		—		—
Mutual Funds		18,216		18,216		—		—
Derivative Assets		4,929		—		4,929		—

Total Assets	$	2,255,183	$	1,070,801	$	1,184,382	$	—

Liabilities
Derivative Liabilities	$	1,815	$	—	$	1,620	$	195

Schedule of Assets and Liabilities Measured at Fair Value as Reported in Consolidated Balance Sheet

The amounts in the table above are reported in the Consolidated Balance Sheet as of March 30, 2014 as follows:


Reported Within:	Total		Level 1		Level 2		Level 3
	(In thousands)
Cash Equivalents	$	1,042,596	$	1,042,596	$	—	$	—
Short-Term Investments		1,462,171		176,879		1,285,292		—
Restricted Cash and Investments		138,637		138,637		—		—
Prepaid Expenses and Other Current Assets		2,487		—		2,487		—
Other Assets		28,559		28,559		—		—

Total Assets	$	2,674,450	$	1,386,671	$	1,287,779	$	—

Accrued Expenses and Other Current Liabilities	$	1,190	$	—	$	1,190	$	—
Other Non-current Liabilities		150		—		—		150

Total Liabilities	$	1,340	$	—	$	1,190	$	150

The amounts in the table above are reported in the Consolidated Balance Sheet as of June 30, 2013 as follows:


Reported Within:	Total		Level 1		Level 2		Level 3
	(In thousands)
Cash Equivalents	$	725,311	$	725,311	$	—	$	—
Short-Term Investments		1,334,746		155,293		1,179,453		—
Restricted Cash and Investments		164,885		164,885		—		—
Prepaid Expenses and Other Current Assets		4,929		—		4,929		—
Other Assets		25,312		25,312		—		—

Total Assets	$	2,255,183	$	1,070,801	$	1,184,382	$	—

Accrued Expenses and Other Current Liabilities	$	1,620	$	—	$	1,620	$	—
Other Non-current Liabilities		195		—		—		195

Total Liabilities	$	1,815	$	—	$	1,620	$	195

Summary of Investments

The following tables summarize the Company’s investments:


	March 30, 2014									June 30, 2013
	Cost		Unrealized Gain		Unrealized (Loss)			Fair Value		Cost		Unrealized Gain		Unrealized Loss			Fair Value
	(In thousands)									(In thousands)
Cash	$	254,982	$	—	$	—		$	254,982	$	438,813	$	—	$	—		$	438,813
Fixed Income Money Market Funds		1,042,596		—		—			1,042,596		725,311		—		—			725,311
Municipal Notes and Bonds		248,050		927		(28	)		248,949		268,390		805		(449	)		268,746
US Treasury and Agencies		183,072		61		(166	)		182,967		155,648		18		(373	)		155,293
Government-Sponsored Enterprises		41,068		51		(30	)		41,089		54,835		65		(95	)		54,805
Foreign Government Bonds		34,979		95		(86	)		34,988		24,950		47		(25	)		24,972
Corporate Notes and Bonds		960,356		1,771		(749	)		961,378		861,109		1,328		(1,945	)		860,492
Mortgage Backed Securities - Residential		26,802		30		(252	)		26,580		27,618		29		(282	)		27,365
Mortgage Backed Securities - Commercial		105,264		141		(548	)		104,857		108,204		426		(672	)		107,958

Total Cash and Short -Term Investments	$	2,897,169	$	3,076	$	(1,859	)	$	2,898,386	$	2,664,878	$	2,718	$	(3,841	)	$	2,663,755

Publicly Traded Equity Security	$	—	$	—	$	—		$	—	$	5,610	$	1,486	$	—		$	7,096
Private Equity Security		—		—		—			—		5,000		—		—			5,000
Mutual Funds		25,656		2,903		—			28,559		16,611		1,619		(14	)		18,216

Total Financial Instruments	$	2,922,825	$	5,979	$	(1,859	)	$	2,926,945	$	2,692,099	$	5,823	$	(3,855	)	$	2,694,067

Reported Within
Cash and Cash Equivalents	$	1,292,301	$	—	$	—		$	1,292,301	$	1,162,473	$	—	$	—		$	1,162,473
Short-Term Investments		1,460,954		3,076		(1,859	)		1,462,171		1,335,868		2,718		(3,841	)		1,334,745
Restricted Cash and Investments		143,914		—		—			143,914		166,536		—		—			166,536
Other assets		25,656		2,903		—			28,559		27,222		3,105		(14	)		30,313

Total	$	2,922,825	$	5,979	$	(1,859	)	$	2,926,945	$	2,692,099	$	5,823	$	(3,855	)	$	2,694,067

Schedule of Fixed Income Securities in Unrealized Loss Positions

The following is an analysis of the Company’s fixed income securities in unrealized loss positions:


	March 30, 2014
	Unrealized Losses					Unrealized Losses
	Less Than 12 Months					12 Months or Greater					Total
	Fair Value		Gross Unrealized Loss			Fair Value		Gross Unrealized Loss			Fair Value		Gross Unrealized Loss
	(In thousands)
Short-Term Investments
Municipal Notes and Bonds	$	17,114	$	(28	)	$	—	$	—		$	17,114	$	(28	)
US Treasury and Agencies		96,394		(166	)		—		—			96,394		(166	)
Government-Sponsored Enterprises		14,071		(30	)		—		—			14,071		(30	)
Foreign Government Bonds		18,487		(86	)		—		—			18,487		(86	)
Corporate Notes and Bonds		261,299		(729	)		6,465		(20	)		267,764		(749	)
Mortgage Backed Securities - Residential		20,974		(243	)		127		(9	)		21,101		(252	)
Mortgage Backed Securities - Commercial		75,081		(404	)		4,249		(144	)		79,330		(548	)

Total Short-Term Investments	$	503,420	$	(1,686	)	$	10,841	$	(173	)	$	514,261	$	(1,859	)

Schedule of Amortized Cost and Fair Value of Cash Equivalents, Short-Term Investments, and Restricted Cash and Investments with Contractual Maturities

The amortized cost and fair value of cash equivalents, short-term investments, and restricted cash and investments with contractual maturities are as follows as of March 30, 2014:


	Cost		Estimated Fair Value
	(in thousands)
Due in one year or less	$	1,316,589	$	1,317,140
Due after one year through five years		1,035,559		1,036,852
Due in more than five years		290,039		289,412

	$	2,642,187	$	2,643,404

Schedule of Outstanding Foreign Currency Forward Contracts

As of March 30, 2014, the Company had the following outstanding foreign currency forward contracts that were entered into under its cash flow and balance sheet hedge program:


	Derivatives Designated as				Derivatives Not Designated as
	Hedging Instruments:				Hedging Instruments:
	(in thousands)
Foreign Currency Forward Contracts
	Buy Contracts		Sell Contracts		Buy Contracts		Sell Contracts
Japanese Yen	$	—	$	123,282	$	—	$	65,959
Swiss Franc						7,496		—
Euro		60,487		—		—		8,901
Korean Won		—		—		36,386		—
Taiwan Dollar		—		—		188,583		65,899

	$	60,487	$	123,282	$	232,465	$	140,759

Schedule of Fair Value of Derivatives Instruments

The fair value of derivative instruments in the Company’s Consolidated Balance Sheets as of March 30, 2014 and June 30, 2013 were as follows:

March 30, 2014

June 30, 2013

Fair Value of Derivative Instruments

Asset Derivatives

Liability Derivatives

Asset Derivatives

Liability Derivatives

Balance Sheet
Location

Fair Value

Balance Sheet
Location

Fair Value

Balance Sheet
Location

Fair Value

Balance Sheet
Location

Fair
Value

(in thousands)

Derivatives designated as hedging instruments:

Foreign exchange forward contracts

Prepaid expense and other assets

2,297

Accrued liabilities

619

Prepaid expense and other assets

4,858

Accrued
liabilities

1,577

Derivatives not designated as hedging instruments:

Foreign exchange forward contracts

Prepaid expense and other assets

190

Accrued liabilities

571

Prepaid expense and other assets

Accrued
liabilities

Total derivatives

2,487

1,190

4,929

1,620

Schedule of Derivative Instruments Designated as Cash Flow Hedges in Statements of Operations Including Accumulated Other Comprehensive Income ("AOCI")


	Three Months Ended March 30, 2014								Nine Months Ended March 30, 2014
	Effective Portion					Ineffective Portion and Amount Excluded from Effectiveness Testing			Effective Portion					Ineffective Portion and Amount Excluded from Effectiveness Testing
Location of Gain (Loss) Recognized in or Reclassified into Income	Gain (Loss) Recognized in AOCI			Gain Reclassified from AOCI into Income		Gain (Loss) Recognized in Income			Gain Recognized in AOCI		Gain Reclassified from AOCI into Income			Gain (Loss) Recognized in Income
	(in thousands)								(in thousands)
Revenue	$	(621	)	$	2,787	$	54		$	7,483	$	8,947		$	232
Cost of goods sold		307			646		(10	)		1,717		1,764			(66	)
Selling, general, and administrative		112			291		(5	)		667		800			(29	)
Other income (expense)		—			—		—			—		—			—

	$	(202	)	$	3,724	$	39		$	9,867	$	11,511		$	137


	Three Months Ended March 31, 2013								Nine Months Ended March 31, 2013
	Effective Portion					Ineffective Portion and Amount Excluded from Effectiveness Testing			Effective Portion					Ineffective Portion and Amount Excluded from Effectiveness Testing
Location of Gain (Loss) Recognized in or Reclassified into Income	Gain (Loss) Recognized in AOCI			Gain Reclassified from AOCI into Income		Gain (Loss) Recognized in Income			Gain Recognized in AOCI		Gain (Loss) Reclassified from AOCI into Income			Gain (Loss) Recognized in Income
	(in thousands)								(in thousands)
Revenue	$	9,454		$	3,850	$	78		$	8,159	$	4,574		$	274
Cost of goods sold		(563	)		1,194		(44	)		1,332		(1,069	)		(208	)
Selling, general, and administrative		(491	)		345		(20	)		537		(405	)		(100	)
Other income (expense)		—			—		—			—		—			(8	)

	$	8,400		$	5,389	$	14		$	10,028	$	3,100		$	(42	)

The effect of derivative instruments not designated as cash flow hedges on the Company’s Condensed Consolidated Statements of Operations was as follows:

Three Months Ended

Nine Months Ended

March 30, 2014

March 31, 2013

March 30, 2014

March 31, 2013

Derivatives Not Designated

as Hedging Instruments:

Location of Gain (Loss) Recognized in
Income

Loss
Recognized
in Income

Gain
Recognized
in Income

(in thousands)

Foreign Exchange Contracts

Other income (expense)

(6,527

)

2,061

4,512

2,347

INVENTORIES (Tables)

9 Months Ended

Mar. 30, 2014

Schedule of Inventories

Inventories consist of the following:


	March 30,		June 30,
	2014		2013
	(in thousands)
Raw materials	$	440,772	$	312,484
Work-in-process		114,890		101,530
Finished goods		161,694		145,303

	$	717,356	$	559,317

PROPERTY AND EQUIPMENT, NET (Tables)

9 Months Ended

Mar. 30, 2014

Schedule of Property and Equipment Net

Property and equipment, net, consists of the following:


	March 30,			June 30,
	2014			2013
	(in thousands)
Manufacturing, engineering and office equipment	$	590,505		$	521,047
Computer equipment and software		128,753			120,144
Land		55,951			65,360
Buildings		207,537			249,126
Leasehold improvements		79,152			76,225
Furniture and fixtures		24,824			21,110

		1,086,722			1,053,012
Less: accumulated depreciation and amortization		(534,131	)		(449,102	)

	$	552,591		$	603,910

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Mar. 30, 2014

Schedule of Finite-Lived Intangible Assets

The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of March 30, 2014:


	Gross		Accumulated Amortization			Net		Weighted-Average Useful Life
	(in thousands)							(years)
Customer relationships	$	625,072	$	(156,121	)	$	468,951		9.01
Existing technology		662,357		(207,981	)		454,376		6.96
Patents		32,053		(23,887	)		8,166		6.09
Other intangible assets		35,216		(35,216	)		—		4.10

Intangible assets subject to amortization		1,354,698		(423,205	)		931,493
In process research and development		11,000					11,000
Development rights		9,100					9,100

Intangible assets not subject to amortization		20,100					20,100

Total intangible assets	$	1,374,798	$	(423,205	)	$	951,593

The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of June 30, 2013 (in thousands, except years):


	Gross		Accumulated Amortization			Net		Weighted-Average Useful Life
	(in thousands)							(years)
Customer relationships	$	624,686	$	(103,519	)	$	521,167		9.01
Existing technology		653,628		(139,894	)		513,734		6.97
Patents		32,053		(22,036	)		10,017		6.09
Backlog		10,000		(10,000	)		—		1.00
Other intangible assets		35,216		(34,889	)		327		4.10

Intangible assets subject to amortization		1,355,583		(310,338	)		1,045,245
In process research and development		20,000					20,000
Development rights		9,100					9,100

Intangible assets not subject to amortization		29,100					29,100

Total intangible assets	$	1,384,683	$	(310,338	)	$	1,074,345

Schedule of Indefinite-Lived Intangible Assets

The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of March 30, 2014:


	Gross		Accumulated Amortization			Net		Weighted-Average Useful Life
	(in thousands)							(years)
Customer relationships	$	625,072	$	(156,121	)	$	468,951		9.01
Existing technology		662,357		(207,981	)		454,376		6.96
Patents		32,053		(23,887	)		8,166		6.09
Other intangible assets		35,216		(35,216	)		—		4.10

Intangible assets subject to amortization		1,354,698		(423,205	)		931,493
In process research and development		11,000					11,000
Development rights		9,100					9,100

Intangible assets not subject to amortization		20,100					20,100

Total intangible assets	$	1,374,798	$	(423,205	)	$	951,593

The following table provides details of the Company’s intangible assets, including the impact of foreign currency translation adjustments, as of June 30, 2013 (in thousands, except years):


	Gross		Accumulated Amortization			Net		Weighted-Average Useful Life
	(in thousands)							(years)
Customer relationships	$	624,686	$	(103,519	)	$	521,167		9.01
Existing technology		653,628		(139,894	)		513,734		6.97
Patents		32,053		(22,036	)		10,017		6.09
Backlog		10,000		(10,000	)		—		1.00
Other intangible assets		35,216		(34,889	)		327		4.10

Intangible assets subject to amortization		1,355,583		(310,338	)		1,045,245
In process research and development		20,000					20,000
Development rights		9,100					9,100

Intangible assets not subject to amortization		29,100					29,100

Total intangible assets	$	1,384,683	$	(310,338	)	$	1,074,345

Estimated Future Amortization Expense of Intangible Assets

The estimated future amortization expense of purchased intangible assets as of March 30, 2014 is as follows:


Fiscal Year	Amount
	(in thousands)
2014 (3 months)	$	39,842
2015		159,718
2016		157,510
2017		155,790
2018		154,625
Thereafter		264,008

	$	931,493

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)

9 Months Ended

Mar. 30, 2014

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:


	March 30,		June 30,
	2014		2013
	(in thousands)
Accrued compensation	$	283,594	$	254,795
Warranty reserves		71,489		52,252
Income and other taxes payable		51,178		39,420
Other		109,243		118,061

	$	515,504	$	464,528

OTHER EXPENSE, NET (Tables)

9 Months Ended

Mar. 30, 2014

Components of Other Expense Net

The significant components of other expense, net, are as follows:


	Three Months Ended						Nine Months Ended
	March 30,			March 31,			March 30,			March 31,
	2014			2013			2014			2013
	(in thousands)
Interest income	$	3,110		$	3,235		$	8,661		$	11,411
Interest expense		(15,621	)		(15,175	)		(46,220	)		(45,294	)
Gains on deferred compensation plan related assets		3,137			3,112			8,534			7,087
Foreign exchange gains (losses)		(85	)		(1,294	)		(181	)		(4,936	)
Other, net		(396	)		(5,712	)		1,252			(7,430	)

	$	(9,855	)	$	(15,834	)	$	(27,954	)	$	(39,162	)

NET INCOME PER SHARE (Tables)

9 Months Ended

Mar. 30, 2014

Schedule of Numerators and Denominators of Basic and Diluted Computations for Net Income Per Share

The following table reconciles the numerators and denominators of the basic and diluted computations for net income per share.


	Three Months Ended				Nine Months Ended
	March 30,		March 31,		March 30,		March 31,
	2014		2013		2014		2013
	(in thousands, except per share data)
Numerator:
Net income	$	164,396	$	18,996	$	398,894	$	28,172

Denominator:
Basic average shares outstanding		162,238		163,034		161,904		171,016
Effect of potential dilutive securities:
Employee stock plans		2,641		2,729		2,810		2,390
Convertible notes		6,757		2,741		6,337		900

Diluted average shares outstanding		171,636		168,504		171,051		174,306

Net income per share - basic	$	1.01	$	0.12	$	2.46	$	0.16

Net income per share - diluted	$	0.96	$	0.11	$	2.33	$	0.16

Schedule of Potentially Dilutive Securities Excluded from EPS Calculations

The following potentially dilutive securities were excluded:

Three Months Ended

Nine Months Ended

March 30,

March 31,

March 30,

March 31,

2014

2013

2014

2013

(in thousands)

Number of potential dilutive securities excluded

298

567

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

9 Months Ended

Mar. 30, 2014

Components of Accumulated Other Comprehensive Income or Loss

The components of accumulated other comprehensive income (loss), net of tax at the end of the period, as well as the activity during the period, were as follows:


	Accumulated foreign currency translation adjustment			Accumulated unrealized holding gain (loss) on cash flow hedges			Accumulated unrealized holding gain (loss) on available-for-sale investments			Accumulated unrealized components of defined benefit plans			Total
	(in thousands)
Balance as of June 30, 2013	$	(17,178	)	$	2,822		$	(15	)	$	(14,322	)	$	(28,693	)
Other comprehensive income before reclassifications		1,680			8,632			962			534			11,808
Gains reclassified from accumulated other comprehensive income to net income		—			(10,066	)⁽¹⁾		(120	)⁽²⁾		—			(10,186	)

Net current-period other comprehensive income	$	1,680		$	(1,434	)	$	842		$	534		$	1,622

Balance as of March 30, 2014	$	(15,498	)	$	1,388		$	827		$	(13,788	)	$	(27,071	)

(1)	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in revenue: $7,961, cost of goods sold: $1,505 and selling, general and administrative expenses: $600.

(2)	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in other expense, net.

LONG-TERM DEBT AND OTHER BORROWINGS (Tables)

9 Months Ended

Mar. 30, 2014

Schedule of Carrying Value of Convertible Senior Notes and Other Long-Term Debt

The following table reflects the carrying value of the Company’s convertible senior notes and other long-term debt as of March 30, 2014 and June 30, 2013:


	March 30,			June 30,
	2014			2013
	*(in millions)*
0.50% Notes due 2016	$	450.0		$	450.0
Less: Unamortized interest discount		(34.3	)		(45.7	)

Net carrying amount of 0.50% Notes due 2016		415.7			404.3

1.25% Notes due 2018		450.0			450.0
Less: Unamortized interest discount		(66.3	)		(76.9	)

Net carrying amount of 1.25% Notes due 2018		383.7			373.1

2.625% Notes due 2041		699.9			699.9
Less: Unamortized interest discount		(184.2	)		(186.9	)

Net carrying amount of 2.625% Notes due 2041		515.7			513.0

Total debt		1,315.1			1,290.4

Less: current portion of debt		(515.7	)		(513.0	)

Long-term debt	$	799.4		$	777.4

Schedule of Recognized Interest Cost Relating to Both Contractual Interest Coupon and Amortization of Discount on Liability Component of Notes

The following table presents the amount of interest cost recognized relating to both the contractual interest coupon and amortization of the discount on the liability component of the Notes during the three and nine months ended March 30, 2014 and March 31, 2013.


	Three Months Ended				Nine Months Ended
	March 30,		March 31,		March 30,		March 31,
	2014		2013		2014		2013
	*(in millions)*
Contractual interest coupon	$	6.6	$	6.6		19.7		19.7
Amortization of interest discount		8.3		7.9		24.7		23.5
Amortization of issuance costs		0.6		0.6		1.8		1.8

Total interest cost recognized	$	15.5	$	15.1	$	46.2	$	45.0

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

COMMITMENTS (Tables)

9 Months Ended

Mar. 30, 2014

Schedule of Changes in Product Warranty Reserves

Changes in the Company’s product warranty reserves were as follows:


	Three Months Ended						Nine Months Ended
	March 30,			March 31,			March 30,			March 31,
	2014			2013			2014			2013
	(in thousands)
Balance at beginning of period	$	67,413		$	62,922		$	58,078		$	70,161
Warranties issued during the period		25,106			18,829			67,405			53,377
Settlements made during the period		(19,686	)		(27,101	)		(52,958	)		(72,960	)
Changes in liability for pre-existing warranties		(258	)		90			50			4,162

Balance at end of period	$	72,575		$	54,740		$	72,575		$	54,740

STOCK REPURCHASE PROGRAM (Tables)

9 Months Ended

Mar. 30, 2014

Schedule of Repurchases under 2013 Repurchase Program

Repurchases under the 2013 repurchase program were as follows during the periods indicated:


Period	Total Number of Shares Repurchased		Total Cost of Repurchase		Average Price Paid Per Share*		Amount Available Under Repurchase Program
	(in thousands, except per share data)
Available balance as of June 30, 2013							$	250,000
Quarter ended September 29, 2013		1,935	$	96,462	$	48.06	$	153,538
Quarter ended December 29, 2013		762	$	39,800	$	52.20	$	113,738
Quarter ended March 30, 2014		930	$	49,414	$	53.13	$	64,324

Equity Based Compensation Plans - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options and restricted stock units vesting period, years			3 years
The total intrinsic value of options exercised	$ 7.1	$ 8.0	$ 29.3	$ 12.7
Unrecognized compensation expense, stock option	5.9		5.9
Stock compensation expense	$ 24.3	$ 25.6	$ 70.6	$ 74.1
Novellus Systems Incorporated
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options and restricted stock units vesting period, years			4 years
Existing Stock Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options and RSUs issued and outstanding under stock plans	6,395,328		6,395,328
Shares available for future issuance under stock plan	11,008,283		11,008,283
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining period for recognition, years			1 year 8 months 12 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining period for recognition, years			1 year 10 months 24 days
Unrecognized compensation expense	$ 130.3		$ 130.3
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining period for recognition, years			5 months
Unrecognized compensation expense	$ 5.7		$ 5.7
Number of shares available for purchase under ESPP	8,741,208		8,741,208
ESPP purchase price per share as percentage of fair market value			85.00%
Performance Based Restricted Stock Units (PRSU)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options and RSUs issued and outstanding under stock plans	600,000		600,000
Stock compensation expense	$ 1.2		$ 1.2
Performance Based Restricted Stock Units (PRSU) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock to be issued, vesting percentage			0.00%
Performance Based Restricted Stock Units (PRSU) \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock to be issued, vesting percentage			150.00%

Recognized Equity Based Compensation Expenses and Related Income Tax Benefit (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity-based compensation expense	$ 24.3	$ 25.6	$ 70.6	$ 74.1
Income tax benefit related to equity-based compensation expense	$ 4.1	$ 4.3	$ 11.7	$ 13.3

Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 30, 2014	Jun. 30, 2013
Options
Beginning balance	2,571
Granted	$ 166
Exercised	(1,065)
Forfeited or expired	(1)
Ending balance	1,671	2,571
Exercisable	1,066
Weighted-Average Exercise Price
Beginning balance	$ 26.87
Granted	51.76
Exercised	24.50
Forfeited or expired	29.71
Ending balance	30.86	$ 26.87
Exercisable	$ 24.62
Weighted-Average Remaining Contractual Term (in years)
Outstanding at end of period	4 years 9 months 11 days	4 years 5 months 23 days
Exercisable at March 30, 2014	3 years 10 months 10 days
Aggregate Intrinsic Value
Outstanding at March 30, 2014	$ 39,501
Exercisable at March 30, 2014	$ 31,840

Summary of Restricted Stock Units (Detail) shares in Thousands	9 Months Ended
	Mar. 30, 2014 $ / shares shares
Unvested Restricted Stock Units Weighted-Average Grant Date Fair Value
Granted	$ 166
Restricted Stock Units (RSUs)
Unvested Restricted Stock Units
Beginning balance \| shares	4,842
Granted \| shares	1,376
Vested \| shares	(1,313)
Forfeited \| shares	(181)
Ending balance \| shares	4,724
Unvested Restricted Stock Units Weighted-Average Grant Date Fair Value
Beginning of Period	$ 39.32
Granted	49.47
Vested	39.84
Forfeited	39.48
Ending of Period	$ 42.12

Schedule of Stock Options Weighted Average Assumptions (Detail)	3 Months Ended	9 Months Ended
	Mar. 30, 2014	Mar. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 months 4 days	8 months 5 days
Expected stock price volatility	28.89%	30.24%
Risk-free interest rate	0.09%	0.07%

Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 30, 2014	Jun. 30, 2013
Financial Instruments [Line Items]
Fair value	$ 1,462,171	$ 1,334,746
Derivative Assets	2,487	4,929
Total Assets	2,674,450	2,255,183
Derivative Liabilities	1,340	1,815
Money Market Funds
Financial Instruments [Line Items]
Fair value	1,042,596	725,311
Municipal Notes And Bonds
Financial Instruments [Line Items]
Fair value	248,949	268,746
US Treasury and Agencies
Financial Instruments [Line Items]
Fair value	182,967	155,293
Government-Sponsored Enterprises
Financial Instruments [Line Items]
Fair value	41,089	54,805
Foreign Government Debt Securities
Financial Instruments [Line Items]
Fair value	34,988	24,972
Corporate Notes And Bonds
Financial Instruments [Line Items]
Fair value	961,378	860,492
Mortgage Backed Securities - Residential
Financial Instruments [Line Items]
Fair value	26,580	27,365
Mortgage Backed Securities - Commercial
Financial Instruments [Line Items]
Fair value	104,857	107,958
Publicly Traded Equity Securities
Financial Instruments [Line Items]
Fair value		7,096
Total Short Term Investments
Financial Instruments [Line Items]
Fair value	2,643,404	2,224,942
Mutual Funds
Financial Instruments [Line Items]
Fair value	28,559	18,216
Quoted Prices in Active Markets for Identical Assets (Level 1)
Financial Instruments [Line Items]
Fair value	176,879	155,293
Total Assets	1,386,671	1,070,801
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Money Market Funds
Financial Instruments [Line Items]
Fair value	1,042,596	725,311
Quoted Prices in Active Markets for Identical Assets (Level 1) \| US Treasury and Agencies
Financial Instruments [Line Items]
Fair value	182,967	155,293
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Corporate Notes And Bonds
Financial Instruments [Line Items]
Fair value	132,549	164,885
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Publicly Traded Equity Securities
Financial Instruments [Line Items]
Fair value		7,096
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Total Short Term Investments
Financial Instruments [Line Items]
Fair value	1,358,112	1,045,489
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Mutual Funds
Financial Instruments [Line Items]
Fair value	28,559	18,216
Significant Other Observable Inputs (Level 2)
Financial Instruments [Line Items]
Fair value	1,285,292	1,179,453
Derivative Assets	2,487	4,929
Total Assets	1,287,779	1,184,382
Derivative Liabilities	1,190	1,620
Significant Other Observable Inputs (Level 2) \| Municipal Notes And Bonds
Financial Instruments [Line Items]
Fair value	248,949	268,746
Significant Other Observable Inputs (Level 2) \| Government-Sponsored Enterprises
Financial Instruments [Line Items]
Fair value	41,089	54,805
Significant Other Observable Inputs (Level 2) \| Foreign Government Debt Securities
Financial Instruments [Line Items]
Fair value	34,988	24,972
Significant Other Observable Inputs (Level 2) \| Corporate Notes And Bonds
Financial Instruments [Line Items]
Fair value	828,829	695,607
Significant Other Observable Inputs (Level 2) \| Mortgage Backed Securities - Residential
Financial Instruments [Line Items]
Fair value	26,580	27,365
Significant Other Observable Inputs (Level 2) \| Mortgage Backed Securities - Commercial
Financial Instruments [Line Items]
Fair value	104,857	107,958
Significant Other Observable Inputs (Level 2) \| Total Short Term Investments
Financial Instruments [Line Items]
Fair value	1,285,292	1,179,453
Significant Unobservable Inputs (Level 3)
Financial Instruments [Line Items]
Derivative Liabilities	$ 150	$ 195

Schedule of Assets and Liabilities Measured at Fair Value as Reported in Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 30, 2014	Jun. 30, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash Equivalents	$ 1,042,596	$ 725,311
Short-Term Investments	1,462,171	1,334,746
Restricted Cash and Investments	138,637	164,885
Prepaid Expenses and Other Current Assets	2,487	4,929
Other Assets	28,559	25,312
Total Assets	2,674,450	2,255,183
Accrued Expenses and Other Current Liabilities	1,190	1,620
Other Non-current Liabilities	150	195
Total Liabilities	1,340	1,815
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash Equivalents	1,042,596	725,311
Short-Term Investments	176,879	155,293
Restricted Cash and Investments	138,637	164,885
Other Assets	28,559	25,312
Total Assets	1,386,671	1,070,801
Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Short-Term Investments	1,285,292	1,179,453
Prepaid Expenses and Other Current Assets	2,487	4,929
Total Assets	1,287,779	1,184,382
Accrued Expenses and Other Current Liabilities	1,190	1,620
Total Liabilities	1,190	1,620
Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Other Non-current Liabilities	150	195
Total Liabilities	$ 150	$ 195

Summary of Investments (Detail) - USD ($) $ in Thousands	Mar. 30, 2014	Jun. 30, 2013
Financial Instruments [Line Items]
Fair Value	$ 1,462,171	$ 1,334,746
Cash
Financial Instruments [Line Items]
Cost	254,982	438,813
Fair Value	254,982	438,813
Fixed Income Money Market Funds
Financial Instruments [Line Items]
Cost	1,042,596	725,311
Fair Value	1,042,596	725,311
Municipal Notes And Bonds
Financial Instruments [Line Items]
Cost	248,050	268,390
Unrealized Gain	927	805
Unrealized (Loss)	(28)	(449)
Fair Value	248,949	268,746
US Treasury and Agencies
Financial Instruments [Line Items]
Cost	183,072	155,648
Unrealized Gain	61	18
Unrealized (Loss)	(166)	(373)
Fair Value	182,967	155,293
Government-Sponsored Enterprises
Financial Instruments [Line Items]
Cost	41,068	54,835
Unrealized Gain	51	65
Unrealized (Loss)	(30)	(95)
Fair Value	41,089	54,805
Foreign Government Bonds
Financial Instruments [Line Items]
Cost	34,979	24,950
Unrealized Gain	95	47
Unrealized (Loss)	(86)	(25)
Fair Value	34,988	24,972
Corporate Notes And Bonds
Financial Instruments [Line Items]
Cost	960,356	861,109
Unrealized Gain	1,771	1,328
Unrealized (Loss)	(749)	(1,945)
Fair Value	961,378	860,492
Mortgage Backed Securities - Residential
Financial Instruments [Line Items]
Cost	26,802	27,618
Unrealized Gain	30	29
Unrealized (Loss)	(252)	(282)
Fair Value	26,580	27,365
Mortgage Backed Securities - Commercial
Financial Instruments [Line Items]
Cost	105,264	108,204
Unrealized Gain	141	426
Unrealized (Loss)	(548)	(672)
Fair Value	104,857	107,958
Total Cash And Short Term Investments
Financial Instruments [Line Items]
Cost	2,897,169	2,664,878
Unrealized Gain	3,076	2,718
Unrealized (Loss)	(1,859)	(3,841)
Fair Value	2,898,386	2,663,755
Publicly Traded Equity Securities
Financial Instruments [Line Items]
Cost		5,610
Unrealized Gain		1,486
Fair Value		7,096
Private Equity Securities
Financial Instruments [Line Items]
Cost		5,000
Fair Value		5,000
Mutual Funds
Financial Instruments [Line Items]
Cost	25,656	16,611
Unrealized Gain	2,903	1,619
Unrealized (Loss)		(14)
Fair Value	28,559	18,216
Total Financial Instruments
Financial Instruments [Line Items]
Cost	2,922,825	2,692,099
Unrealized Gain	5,979	5,823
Unrealized (Loss)	(1,859)	(3,855)
Fair Value	2,926,945	2,694,067
Cash and Cash Equivalents
Financial Instruments [Line Items]
Cost	1,292,301	1,162,473
Fair Value	1,292,301	1,162,473
Short-term Investments
Financial Instruments [Line Items]
Cost	1,460,954	1,335,868
Unrealized Gain	3,076	2,718
Unrealized (Loss)	(1,859)	(3,841)
Fair Value	1,462,171	1,334,745
Restricted Cash And Investments
Financial Instruments [Line Items]
Cost	143,914	166,536
Fair Value	143,914	166,536
Other Assets
Financial Instruments [Line Items]
Cost	25,656	27,222
Unrealized Gain	2,903	3,105
Unrealized (Loss)		(14)
Fair Value	28,559	30,313
Total
Financial Instruments [Line Items]
Cost	2,922,825	2,692,099
Unrealized Gain	5,979	5,823
Unrealized (Loss)	(1,859)	(3,855)
Fair Value	$ 2,926,945	$ 2,694,067

Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013	Jun. 30, 2013
Financial Instruments [Line Items]
Other than temporary impairment included in net realized gains (losses)	$ 0		$ 0
Gains realized from sales of investments	400	$ 200	800	$ 1,400
Losses realized from sales of investments	$ (700)	(400)	$ (1,700)	(1,100)
Investment classified as short term, maturity period	1 year		1 year
Gains (losses) accumulated in Other Comprehensive Income expects to reclassify from Other Comprehensive Income into earnings	$ 1,400		$ 1,400
Net derivative asset from master netting agreements	2,487		2,487		$ 4,929
Foreign Exchange Forward Contracts \| Cash flow hedging
Financial Instruments [Line Items]
Potential effect of rights of set-off under master netting agreements for foreign exchange contracts assets	700		700		1,600
Potential effect of rights of set-off under master netting agreements for foreign exchange contracts liabilities	700		700		1,600
Net derivative asset from master netting agreements	$ 1,300		$ 1,300		$ 3,300
Publicly Equity Investment
Financial Instruments [Line Items]
Other than temporary impairment included in net realized gains (losses)		$ 3,700		$ 3,700
Maximum
Financial Instruments [Line Items]
Foreign currency forward contract, expiration period			24 months
Maximum \| Majority of Contracts
Financial Instruments [Line Items]
Foreign currency forward contract, expiration period			12 months

Schedule of Fixed Income Securities in Unrealized Loss Positions (Detail) $ in Thousands	Mar. 30, 2014 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Unrealized Losses Less Than 12 Months - Fair Value	$ 503,420
Unrealized Losses Less Than 12 Months - Unrealized	(1,686)
Unrealized Losses 12 Months or Greater - Fair Value	10,841
Unrealized Losses 12 Months or Greater - Unrealized	(173)
Total - Fair Value	514,261
Total - Unrealized	(1,859)
Municipal Notes And Bonds
Schedule of Available-for-sale Securities [Line Items]
Unrealized Losses Less Than 12 Months - Fair Value	17,114
Unrealized Losses Less Than 12 Months - Unrealized	(28)
Total - Fair Value	17,114
Total - Unrealized	(28)
US Treasury and Agencies
Schedule of Available-for-sale Securities [Line Items]
Unrealized Losses Less Than 12 Months - Fair Value	96,394
Unrealized Losses Less Than 12 Months - Unrealized	(166)
Total - Fair Value	96,394
Total - Unrealized	(166)
Government-Sponsored Enterprises
Schedule of Available-for-sale Securities [Line Items]
Unrealized Losses Less Than 12 Months - Fair Value	14,071
Unrealized Losses Less Than 12 Months - Unrealized	(30)
Total - Fair Value	14,071
Total - Unrealized	(30)
Foreign Government Bonds
Schedule of Available-for-sale Securities [Line Items]
Unrealized Losses Less Than 12 Months - Fair Value	18,487
Unrealized Losses Less Than 12 Months - Unrealized	(86)
Total - Fair Value	18,487
Total - Unrealized	(86)
Corporate Notes And Bonds
Schedule of Available-for-sale Securities [Line Items]
Unrealized Losses Less Than 12 Months - Fair Value	261,299
Unrealized Losses Less Than 12 Months - Unrealized	(729)
Unrealized Losses 12 Months or Greater - Fair Value	6,465
Unrealized Losses 12 Months or Greater - Unrealized	(20)
Total - Fair Value	267,764
Total - Unrealized	(749)
Mortgage Backed Securities - Residential
Schedule of Available-for-sale Securities [Line Items]
Unrealized Losses Less Than 12 Months - Fair Value	20,974
Unrealized Losses Less Than 12 Months - Unrealized	(243)
Unrealized Losses 12 Months or Greater - Fair Value	127
Unrealized Losses 12 Months or Greater - Unrealized	(9)
Total - Fair Value	21,101
Total - Unrealized	(252)
Mortgage Backed Securities - Commercial
Schedule of Available-for-sale Securities [Line Items]
Unrealized Losses Less Than 12 Months - Fair Value	75,081
Unrealized Losses Less Than 12 Months - Unrealized	(404)
Unrealized Losses 12 Months or Greater - Fair Value	4,249
Unrealized Losses 12 Months or Greater - Unrealized	(144)
Total - Fair Value	79,330
Total - Unrealized	$ (548)

Schedule of Amortized Cost and Fair Value of Cash Equivalents, Short-Term Investments, and Restricted Cash and Investments with Contractual Maturities (Detail) - USD ($) $ in Thousands	Mar. 30, 2014	Jun. 30, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in one year or less, Cost	$ 1,316,589
Due in one year or less, Estimated Fair Value	1,317,140
Due after one year through five years, Cost	1,035,559
Due after one year through five years, Estimated Fair Value	1,036,852
Due in more than five years, Cost	290,039
Due in more than five years, Estimated Fair Value	289,412
Cost	2,642,187
Estimated Fair Value	1,462,171	$ 1,334,746
Total Short Term Investments
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Estimated Fair Value	$ 2,643,404

Schedule of Outstanding Foreign Currency Forward Contracts (Detail) $ in Thousands	Mar. 30, 2014 USD ($)
Buy Contracts
Derivative [Line Items]
Derivatives Designated as Hedging Instruments	$ 60,487
Derivatives Not Designated as Hedging Instruments	232,465
Buy Contracts \| Switzerland, Francs
Derivative [Line Items]
Derivatives Not Designated as Hedging Instruments	7,496
Buy Contracts \| Euro
Derivative [Line Items]
Derivatives Designated as Hedging Instruments	60,487
Buy Contracts \| Korean Won
Derivative [Line Items]
Derivatives Not Designated as Hedging Instruments	36,386
Buy Contracts \| Taiwan Dollar
Derivative [Line Items]
Derivatives Not Designated as Hedging Instruments	188,583
Sell Contracts
Derivative [Line Items]
Derivatives Designated as Hedging Instruments	123,282
Derivatives Not Designated as Hedging Instruments	140,759
Sell Contracts \| Japanese Yen
Derivative [Line Items]
Derivatives Designated as Hedging Instruments	123,282
Derivatives Not Designated as Hedging Instruments	65,959
Sell Contracts \| Euro
Derivative [Line Items]
Derivatives Not Designated as Hedging Instruments	8,901
Sell Contracts \| Taiwan Dollar
Derivative [Line Items]
Derivatives Not Designated as Hedging Instruments	$ 65,899

Schedule of Fair Value of Derivatives Instruments (Detail) - USD ($) $ in Thousands	Mar. 30, 2014	Jun. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset Derivatives, Fair Value	$ 2,487	$ 4,929
Liability Derivatives, Fair Value	1,190	1,620
Derivatives Designated As Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset Derivatives, Fair Value	2,297	4,858
Liability Derivatives, Fair Value	619	1,577
Derivatives Not Designated as Hedging Instruments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset Derivatives, Fair Value	190	71
Liability Derivatives, Fair Value	$ 571	$ 43

Schedule of Derivative Instruments Designated as Cash Flow Hedges in Statements of Operations Including Accumulated Other Comprehensive Income ("AOCI") (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (Loss) Recognized in AOCI (Effective Portion)	$ (202)	$ 8,400	$ 9,867	$ 10,028
Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	3,724	5,389	11,511	3,100
Gain (Loss) Recognized (Excluded from Effectiveness Testing)	39	14	137	(42)
Located in revenue
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (Loss) Recognized in AOCI (Effective Portion)	(621)	9,454	7,483	8,159
Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	2,787	3,850	8,947	4,574
Gain (Loss) Recognized (Excluded from Effectiveness Testing)	54	78	232	274
Located in cost of goods sold
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (Loss) Recognized in AOCI (Effective Portion)	307	(563)	1,717	1,332
Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	646	1,194	1,764	(1,069)
Gain (Loss) Recognized (Excluded from Effectiveness Testing)	(10)	(44)	(66)	(208)
Located in selling, general, and adminstrative
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (Loss) Recognized in AOCI (Effective Portion)	112	(491)	667	537
Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	291	345	800	(405)
Gain (Loss) Recognized (Excluded from Effectiveness Testing)	(5)	(20)	(29)	(100)
Located in other income (expense)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (Loss) Recognized (Excluded from Effectiveness Testing)				(8)
Foreign Exchange Forward Contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Gain (Loss) Recognized	$ (6,527)	$ 2,061	$ 4,512	$ 2,347

Schedule of Inventories (Detail) - USD ($)
$ in Thousands

Mar. 30, 2014

Jun. 30, 2013

Inventory [Line Items]

Raw materials

$ 440,772

$ 312,484

Work-in-process

114,890

101,530

Finished goods

161,694

145,303

Total inventories

$ 717,356

$ 559,317

^[1]

[1]	Derived from audited financial statements

Schedule of Property and Equipment Net (Detail) - USD ($)
$ in Thousands

Mar. 30, 2014

Jun. 30, 2013

Property, Plant and Equipment [Line Items]

Manufacturing, engineering and office equipment

$ 590,505

$ 521,047

Computer equipment and software

128,753

120,144

Land

55,951

65,360

Buildings

207,537

249,126

Leasehold improvements

79,152

76,225

Furniture and fixtures

24,824

21,110

Property and equipment, gross

1,086,722

1,053,012

Less: accumulated depreciation and amortization

(534,131)

(449,102)

Property and equipment, net

$ 552,591

$ 603,910

^[1]

[1]	Derived from audited financial statements

Property and Equipment, Net - Additional Information (Detail) $ in Millions	Mar. 30, 2014 USD ($)
Property, Plant and Equipment [Line Items]
Assets held-for-sale	$ 69

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Mar. 30, 2014

Mar. 31, 2013

Mar. 30, 2014

Mar. 31, 2013

Jun. 30, 2013

^[1]

Goodwill And Intangible Assets [Line Items]

Goodwill

$ 1,457,320

$ 1,452,196

Tax deductible goodwill

61,000

Intangible asset amortization expense

$ 40,400

$ 45,000

$ 122,900

$ 134,300

In Process Research And Development

Goodwill And Intangible Assets [Line Items]

Impairment intangible assets

$ 4,000

[1]	Derived from audited financial statements

Schedule of Intangible Assets (Detail) - USD ($)
$ in Thousands

9 Months Ended

12 Months Ended

Mar. 30, 2014

Jun. 30, 2013

Goodwill And Intangible Assets [Line Items]

Gross intangible assets subject to amortization

$ 1,354,698

$ 1,355,583

Total gross intangible assets

1,374,798

1,384,683

Accumulated Amortization

(423,205)

(310,338)

Net intangible assets subject to amortization

931,493

1,045,245

Intangible assets, net

951,593

1,074,345

^[1]

Intangible assets not subject to amortization

20,100

29,100

Intangible assets not subject to amortization

20,100

29,100

In Process Research And Development

Goodwill And Intangible Assets [Line Items]

Intangible assets not subject to amortization

11,000

20,000

Intangible assets not subject to amortization

11,000

20,000

Developed Technology Rights

Goodwill And Intangible Assets [Line Items]

Intangible assets not subject to amortization

9,100

Intangible assets not subject to amortization

9,100

Customer Relationships

Goodwill And Intangible Assets [Line Items]

Gross intangible assets subject to amortization

625,072

624,686

Accumulated Amortization

(156,121)

(103,519)

Net intangible assets subject to amortization

$ 468,951

$ 521,167

Weighted-Average Useful Life (years)

9 years 4 days

Existing Technology

Goodwill And Intangible Assets [Line Items]

Gross intangible assets subject to amortization

$ 662,357

$ 653,628

Accumulated Amortization

(207,981)

(139,894)

Net intangible assets subject to amortization

$ 454,376

$ 513,734

Weighted-Average Useful Life (years)

6 years 11 months 16 days

6 years 11 months 19 days

Patents

Goodwill And Intangible Assets [Line Items]

Gross intangible assets subject to amortization

$ 32,053

Accumulated Amortization

(23,887)

(22,036)

Net intangible assets subject to amortization

$ 8,166

$ 10,017

Weighted-Average Useful Life (years)

6 years 1 month 2 days

Backlog

Goodwill And Intangible Assets [Line Items]

Gross intangible assets subject to amortization

$ 10,000

Accumulated Amortization

$ (10,000)

Weighted-Average Useful Life (years)

1 year

Other Intangible Assets

Goodwill And Intangible Assets [Line Items]

Gross intangible assets subject to amortization

$ 35,216

Accumulated Amortization

$ (35,216)

(34,889)

Net intangible assets subject to amortization

$ 327

Weighted-Average Useful Life (years)

4 years 1 month 6 days

[1]	Derived from audited financial statements

Estimated Future Amortization Expense of Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 30, 2014	Jun. 30, 2013
Finite-Lived Intangible Assets [Line Items]
2014 (3 months)	$ 39,842
2015	159,718
2016	157,510
2017	155,790
2018	154,625
Thereafter	264,008
Net intangible assets subject to amortization	$ 931,493	$ 1,045,245

Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)
$ in Thousands

Mar. 30, 2014

Jun. 30, 2013

Schedule of Accrued Liabilities [Line Items]

Accrued compensation

$ 283,594

$ 254,795

Warranty reserves

71,489

52,252

Income and other taxes payable

51,178

39,420

Other

109,243

118,061

Accrued expenses and other current liabilities

$ 515,504

$ 464,528

^[1]

[1]	Derived from audited financial statements

Components of Other Expense Net (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Component Of Other Expense Income Nonoperating [Line Items]
Interest income	$ 3,110	$ 3,235	$ 8,661	$ 11,411
Interest expense	(15,621)	(15,175)	(46,220)	(45,294)
Gains on deferred compensation plan related assets	3,137	3,112	8,534	7,087
Foreign exchange gains (losses)	(85)	(1,294)	(181)	(4,936)
Other, net	(396)	(5,712)	1,252	(7,430)
Other income (expense), net	$ (9,855)	$ (15,834)	$ (27,954)	$ (39,162)

Income Tax Expense - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Income Tax [Line Items]
Income tax (benefit) expense	$ 17,686	$ (24,011)	$ 34,971	$ (35,761)
Effective income tax rate	9.70%		8.10%
U.S. federal statutory tax rate	35.00%		35.00%

Schedule of Numerators and Denominators of Basic and Diluted Computations for Net Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Schedule of Earnings Per Share, Basic and Diluted, by Common Class [Line Items]
Net income	$ 164,396	$ 18,996	$ 398,894	$ 28,172
Basic average shares outstanding	162,238	163,034	161,904	171,016
Employee stock plans	2,641	2,729	2,810	2,390
Convertible notes	6,757	2,741	6,337	900
Diluted average shares outstanding	171,636	168,504	171,051	174,306
Net income per share - basic	$ 1.01	$ 0.12	$ 2.46	$ 0.16
Net income per share - diluted	$ 0.96	$ 0.11	$ 2.33	$ 0.16

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Schedule of Potentially Dilutive Securities Excluded from EPS Calculations (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of potential dilutive securities excluded	75	298	85	567

Components of Accumulated Other Comprehensive Income or Loss (Detail) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Mar. 30, 2014

Mar. 31, 2013

Mar. 30, 2014

Mar. 31, 2013

Accumulated Other Comprehensive Income (Loss) [Line Items]

Balance as of June 30, 2013

^[1]

$ (28,693)

Other comprehensive income before reclassifications

11,808

Gains reclassified from accumulated other comprehensive income to net income

(10,186)

Net current-period other comprehensive income

$ (11,550)

$ 739

1,622

$ 10,073

Balance as of March 30, 2014

(27,071)

Accumulated Foreign Currency Translation Adjustment

Accumulated Other Comprehensive Income (Loss) [Line Items]

Balance as of June 30, 2013

(17,178)

Other comprehensive income before reclassifications

1,680

Net current-period other comprehensive income

1,680

Balance as of March 30, 2014

(15,498)

Accumulated Unrealized Holding Gains (Losses) on Cash Flow Hedges

Accumulated Other Comprehensive Income (Loss) [Line Items]

Balance as of June 30, 2013

2,822

Other comprehensive income before reclassifications

8,632

Gains reclassified from accumulated other comprehensive income to net income

^[2]

(10,066)

Net current-period other comprehensive income

(1,434)

Balance as of March 30, 2014

1,388

Accumulated Unrealized Holding Gains (Losses) on Available-For-Sale Investments

Accumulated Other Comprehensive Income (Loss) [Line Items]

Balance as of June 30, 2013

(15)

Other comprehensive income before reclassifications

962

Gains reclassified from accumulated other comprehensive income to net income

^[3]

(120)

Net current-period other comprehensive income

842

Balance as of March 30, 2014

827

Accumulated Unrealized Components of Defined Benefit Plans

Accumulated Other Comprehensive Income (Loss) [Line Items]

Balance as of June 30, 2013

(14,322)

Other comprehensive income before reclassifications

534

Net current-period other comprehensive income

534

Balance as of March 30, 2014

$ (13,788)

[1]	Derived from audited financial statements
[2]	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in revenue: $7,961, cost of goods sold: $1,505 and selling, general and administrative expenses: $600.
[3]	Amount of after tax gain reclassified from accumulated other comprehensive income into net income located in other expense, net

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

Components of Accumulated Other Comprehensive Income or Loss (Parenthetical) (Detail) $ in Thousands	9 Months Ended
	Mar. 30, 2014 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from accumulated other comprehensive income	$ 10,186
Reclassified to Revenue
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from accumulated other comprehensive income	7,961
Reclassified to cost of goods sold
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from accumulated other comprehensive income	1,505
Reclassified to selling, general, and administrative
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification from accumulated other comprehensive income	$ 600

Schedule of Carrying Value of Convertible Senior Notes and Other Long-Term Debt (Detail) - USD ($) $ in Millions	Mar. 30, 2014	Jun. 30, 2013	Jun. 24, 2012	May 31, 2011
Debt Instrument [Line Items]
Total long-term debt	$ 1,315.1	$ 1,290.4
Less: current portion of debt	(515.7)	(513.0)
Long-term debt	799.4	777.4
0.50% Notes due 2016
Debt Instrument [Line Items]
Notes due	450.0	450.0		$ 450.0
Less: Unamortized interest discount	(34.3)	(45.7)
Net carrying amount of Notes	415.7	404.3
1.25% Notes due 2018
Debt Instrument [Line Items]
Notes due	450.0	450.0		$ 450.0
Less: Unamortized interest discount	(66.3)	(76.9)
Net carrying amount of Notes	383.7	373.1
2.625% Notes due 2041
Debt Instrument [Line Items]
Notes due	699.9	699.9	$ 700.0
Less: Unamortized interest discount	(184.2)	(186.9)
Net carrying amount of Notes	$ 515.7	$ 513.0

Schedule of Carrying Value of Convertible Senior Notes and Other Long-Term Debt (Parenthetical) (Detail)	9 Months Ended
	Mar. 30, 2014	Jun. 30, 2013	Jun. 24, 2012	May 31, 2011
0.50% Notes due 2016
Debt Instrument [Line Items]
Convertible notes interest rate percentage	0.50%	0.50%		0.50%
Debt instruments maturity date	2016
1.25% Notes due 2018
Debt Instrument [Line Items]
Convertible notes interest rate percentage	1.25%	1.25%		1.25%
Debt instruments maturity date	2018
2.625% Notes due 2041
Debt Instrument [Line Items]
Convertible notes interest rate percentage	2.625%	2.625%	2.625%
Debt instruments maturity date	2041

Long-Term Debt and Other Borrowings - Additional Information (Detail) $ / shares in Units, shares in Millions	1 Months Ended			3 Months Ended			9 Months Ended
	Mar. 12, 2014 USD ($)	Jun. 24, 2012 USD ($) $ / shares	May 31, 2011 USD ($) $ / shares	Mar. 30, 2014 USD ($) $ / shares $ / Right shares	Dec. 29, 2013	Jun. 30, 2013 USD ($)	Mar. 30, 2014 USD ($) $ / shares $ / Right shares
Debt Instrument [Line Items]
Net proceeds from the sale of Convertible Senior Notes			$ 835,500,000
Period of time that common stock sale price for preceding quarter exceeds conversion price				20 days	20 days	20 days
Number of consecutive trading days period required				30 days	30 days	30 days
Revolving credit facility
Debt Instrument [Line Items]
Revolving unsecured credit facility	$ 300,000,000
Credit Facility Maturity Period	Mar. 12, 2019
Additional increase in the facility	$ 200,000,000
Revolving unsecured credit facility maximum borrowing capacity	$ 500,000,000
Consolidated debt to liquidity				$ 1,000,000,000			$ 1,000,000,000
Credit facility outstanding amount				$ 0			0
Revolving credit facility \| Prime Rate
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate				0.50%
Revolving credit facility \| Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate				0.50%
Minimum
Debt Instrument [Line Items]
Stock price percentage of conversion price				130.00%	130.00%	130.00%
Minimum \| Revolving credit facility
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate				0.90%
Minimum \| Revolving credit facility \| London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate				0.00%
Maximum \| Revolving credit facility
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate				1.50%
Total consolidated indebtedness to capitalization ratio				50.00%
Maximum \| Revolving credit facility \| London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument basis spread on variable rate				0.50%
2.625% Notes due 2041
Debt Instrument [Line Items]
Notes due		$ 700,000,000		$ 699,900,000		$ 699,900,000	$ 699,900,000
Convertible notes interest rate percentage		2.625%		2.625%		2.625%	2.625%
Initial conversion rate of common stock shares		28.4781
Principal amount of convertible debt conversion increments		$ 1,000
Convertible Senior Notes conversion price \| $ / shares		$ 35.11
Debt instruments maturity date							2041
Maximum amount of contingent interest rate							2.10%
Initial carrying value of liability component of convertible notes		$ 509,500,000
Discount rate used to determine liability fair value		4.28%
Carrying value of equity components				$ 328,100,000			$ 328,100,000
Effective interest rates on the liability component				4.28%			4.28%
Unamortized discount balance				$ 184,200,000		$ 186,900,000	$ 184,200,000
Remaining life of bond discount, years							27 years 1 month 6 days
If-converted value in excess of aggregate principal amount							$ 386,300,000
Fair value of notes				1,196,900,000			1,196,900,000
0.50% Notes due 2016
Debt Instrument [Line Items]
Notes due			$ 450,000,000	$ 450,000,000		$ 450,000,000	$ 450,000,000
Convertible notes interest rate percentage			0.50%	0.50%		0.50%	0.50%
Initial conversion rate of common stock shares			15.8687
Principal amount of convertible debt conversion increments			$ 1,000
Convertible Senior Notes conversion price \| $ / shares			$ 63.02	$ 63.02			$ 63.02
Debt instruments maturity date							2016
Initial carrying value of liability component of convertible notes			$ 373,800,000
Discount rate used to determine liability fair value			4.29%
Carrying value of equity components				$ 76,200,000			$ 76,200,000
Effective interest rates on the liability component				4.29%			4.29%
Unamortized discount balance				$ 34,300,000		$ 45,700,000	$ 34,300,000
Remaining life of bond discount, years							2 years 1 month 6 days
Warrant conversion price \| $ / Right				71.34			71.34
Shares issued under warrants \| shares				7.1			7.1
Shares of common stock agreed to sell \| shares							7.1
Fair value of notes				$ 518,600,000			$ 518,600,000
0.50% Notes due 2016 \| Convertible Note Hedge
Debt Instrument [Line Items]
Warrant conversion price \| $ / Right				71.34			71.34
1.25% Notes due 2018
Debt Instrument [Line Items]
Notes due			$ 450,000,000	$ 450,000,000		$ 450,000,000	$ 450,000,000
Convertible notes interest rate percentage			1.25%	1.25%		1.25%	1.25%
Initial conversion rate of common stock shares			15.8687
Principal amount of convertible debt conversion increments			$ 1,000
Convertible Senior Notes conversion price \| $ / shares			$ 63.02	$ 63.02			$ 63.02
Debt instruments maturity date							2018
Initial carrying value of liability component of convertible notes			$ 345,100,000
Discount rate used to determine liability fair value			5.27%
Carrying value of equity components				$ 104,900,000			$ 104,900,000
Effective interest rates on the liability component				5.27%			5.27%
Unamortized discount balance				$ 66,300,000		$ 76,900,000	$ 66,300,000
Remaining life of bond discount, years							4 years 1 month 6 days
Warrant conversion price \| $ / Right				76.10			76.10
Shares issued under warrants \| shares				7.1			7.1
Shares of common stock agreed to sell \| shares							7.1
Fair value of notes				$ 558,400,000			$ 558,400,000
1.25% Notes due 2018 \| Convertible Note Hedge
Debt Instrument [Line Items]
Warrant conversion price \| $ / Right				76.10			76.10

Schedule of Recognized Interest Cost Relating to Both Contractual Interest Coupon and Amortization of Discount on Liability Component of Notes (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Debt Instrument [Line Items]
Amortization of interest discount			$ 24,652	$ 23,530
2016, 2018 and 2041 Senior Notes
Debt Instrument [Line Items]
Contractual interest coupon	$ 6,600	$ 6,600	19,700	19,700
Amortization of interest discount	8,300	7,900	24,700	23,500
Amortization of issuance costs	600	600	1,800	1,800
Total interest cost recognized	$ 15,500	$ 15,100	$ 46,200	$ 45,000

Commitments - Additional Information (Detail)
$ in Thousands

9 Months Ended

12 Months Ended

Mar. 30, 2014

USD ($)

Dec. 31, 2013

Leases

Jun. 30, 2013

USD ($)

^[1]

Commitments [Line Items]

Operating Lease purchase option notification period, days

30 days

Restricted collateral for leasing arrangements

$ 143,914

$ 166,536

Operating Lease Cash Collateral

Commitments [Line Items]

Restricted collateral for leasing arrangements

132,500

Operating Lease Marketable Securities Collateral

Commitments [Line Items]

Restricted collateral for leasing arrangements

$ 6,100

Amended

Commitments [Line Items]

Approximate Operating Lease term, years

7 years

Operating Leases expiration date

Dec. 31, 2020

Operating Leases

Commitments [Line Items]

Number of operating leases extinguished | Leases

Operating Lease residual value of guarantee, maximum

$ 191,200

Maximum percentage of aggregate investment value guaranteed

100.00%

Guarantee Obligation Maximum Exposure

$ 220,000

Operating Leases | Amended And Restated

Commitments [Line Items]

Number of operating leases | Leases

Operating Leases | Amended

Commitments [Line Items]

Number of operating leases | Leases

Standby Letters of Credit

Commitments [Line Items]

Guarantee Obligation Maximum Exposure

$ 20,900

[1]	Derived from audited financial statements

Schedule of Changes in Product Warranty Reserves (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 30, 2014	Mar. 31, 2013	Mar. 30, 2014	Mar. 31, 2013
Product Warranty Liability [Line Items]
Balance at beginning of period	$ 67,413	$ 62,922	$ 58,078	$ 70,161
Warranties issued during the period	25,106	18,829	67,405	53,377
Settlements made during the period	(19,686)	(27,101)	(52,958)	(72,960)
Changes in liability for pre-existing warranties	(258)	90	50	4,162
Balance at end of period	$ 72,575	$ 54,740	$ 72,575	$ 54,740

Restructuring and Impairments - Additional Information (Detail) $ in Millions	Mar. 30, 2014 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring liability assumed in the Novellus acquisition	$ 10.3

Stock Repurchase Program - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

9 Months Ended

Apr. 30, 2014

Oct. 28, 2013

Apr. 30, 2013

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Mar. 30, 2014

Mar. 31, 2013

Stock Repurchase Program [Line Items]

Net shares of settlements to cover tax withholding obligations

468,585

Amount paid for shares under net share settlements

$ 23,900

Treasury stock purchases

204,610

$ 953,386

Total Number of Shares Repurchased

930,000

762,000

1,935,000

Treasury stock purchases, weighted average share price

^[1]

$ 53.13

$ 52.20

$ 48.06

Treasury stock, at cost

$ 75,000

Maximum

Stock Repurchase Program [Line Items]

Total Number of Shares Repurchased

1,700,000

Repurchase Of Equity | Maximum

Stock Repurchase Program [Line Items]

Authorized repurchase of Company common stock

$ 250,000

Subsequent Event | Repurchase Of Equity | Maximum

Stock Repurchase Program [Line Items]

Authorized repurchase of Company common stock

$ 850,000

Share Repurchase Program Final Settlement

Stock Repurchase Program [Line Items]

Total Number of Shares Repurchased

Treasury stock purchases, weighted average share price

$ 50.40

Share Repurchase Arrangements

Stock Repurchase Program [Line Items]

Treasury stock purchases

$ 75,000

Share Repurchase Arrangements | Initial delivery

Stock Repurchase Program [Line Items]

Total Number of Shares Repurchased

1,200,000

Share Repurchase Arrangements | Subsequent delivery

Stock Repurchase Program [Line Items]

Total Number of Shares Repurchased

300,000

[1]

Average price paid per share excludes accelerated share repurchases for which cost was incurred during the September 2013 quarter, but that did not settle until the December 2013 quarter. See Collared Accelerated Share Repurchases section below for details regarding average price associated with these transactions.

Schedule of Repurchases under 2013 Repurchase Program (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands

3 Months Ended

12 Months Ended

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Stock Repurchase Program [Line Items]

Total Number of Shares Repurchased

930

762

1,935

Total Cost of Repurchase

$ 49,414

$ 39,800

$ 96,462

Average Price Paid Per Share

^[1]

$ 53.13

$ 52.20

$ 48.06

Amount Available Under Repurchase Program

$ 64,324

$ 113,738

$ 153,538

$ 250,000

[1]

Average price paid per share excludes accelerated share repurchases for which cost was incurred during the September 2013 quarter, but that did not settle until the December 2013 quarter. See Collared Accelerated Share Repurchases section below for details regarding average price associated with these transactions.

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Apr. 30, 2014	Apr. 30, 2013
Repurchase Of Equity \| Maximum
Subsequent Event [Line Items]
Authorized repurchase of Company common stock		$ 250
Subsequent Event \| Repurchase Of Equity \| Maximum
Subsequent Event [Line Items]
Authorized repurchase of Company common stock	$ 850
Subsequent Event \| Dividend Declared [Member]
Subsequent Event [Line Items]
Declared dividend	$ 0.18